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Abstract 
Psychiatric and neurodevelopmental disorders are characterized by alterations in neural 
circuits that emerge into cognitive deficits. The cellular mechanisms that underpin the 
plasticity and dynamics of these conditions, namely Schizophrenia, remain unclear. Thus, 
proper model systems are required for further investigation into the underlying aetiology. 
Moreover, while animal models and post-mortem studies have provided important insight, 
both have limitations and it is necessary to explore the effects in human neurons.  
Estrogens have been widely documented by their effects not only in the regulation of the 
reproductive behavior but for its effects in different cognitive functions in both male and 
female. Recent studies have classified 17-β estradiol (most representative active form) as a 
neurosteroid and neuromodulator, demonstrating its ability to modulate neuronal activity and 
being able to manifest rapid effects in specific areas of the brain. Moreover, testosterone as 
an estrogen precursor participates on estradiol ―de novo‖ synthesis in the brain being also 
reported to influence neurobiological processes as stimulation of neurite outgrowth [1].  
During adolescence, the development of Schizophrenia has been associated to the use of 
cannabis [2]. Investigations over the effects of the plant-derived cannabinoid in the human 
brain enabled the discovery of the endogenous cannabinoids (endocannabinoids), synthesized 
within mammal tissues. Endocannabinoids modulate the human brain since early stages of 
development, influencing neurobiological processes as cell proliferation and differentiation 
[3].  
Therefore, this thesis investigates the effects of neurosteroids and endocannabinoids in 
Schizophrenia, with the aim to identify potential novel therapeutic avenues. In order to 
achieve this objective I differentiated cortical neurons from induced pluripotent stem cells 
derived from healthy control males and studied the effects of the different treatments on 
neuronal morphology. 
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  Chapter 1.
 Introduction  
1.1. Motivation 
 
Schizophrenia is a severe neurodevelopmental disorder, nowadays defined as a chronic, 
disabling mental disorder. Several approaches have been used to investigate the disorder. 
Pharmacological, magnetic resonance imaging (MRI) and post-mortem studies have revealed a 
decrease in brain volume, aberrant neurotransmitter signalling, reduced dendritic 
arborization and impaired myelination in schizophrenic brains. However, despite the 
investigations that surround this disorder, the clinical treatment has low efficacy since the 
aetiology and neurobiological systems that underlie the disease are poorly understood. The 
complex genetic and varying environmental risk factors that contribute to this disorder make 
the need of proper model systems of supreme relevance to further its study and to develop 
therapeutics.  
The use of cannabinoids during adolescence has been considered as a potential risk factor 
of Schizophrenia for individuals with genetic predisposition for the disorder [4]. Further 
studies revealed that cannabinoid receptors can be also activated by endogenous 
cannabinoids/endocannabinoids. The endocannabinoid system has been reported to influence 
neuronal development since early embryonic stages [3], being involved in cell proliferation, 
differentiation and cell survival. Further investigations have been revealing the effects of 
endocannabinoids in cognition and the potentialities of its use in the treatment of different 
disorders including Schizophrenia [2]. Therefore it is important to understand the effects and 
mechanisms of this system for future medical application.  
Moreover neurosteroids, such as estrogens and testosterone, have a great influence in 
cognitive and memory processing, which has been demonstrated by their ability to modulate 
synaptic plasticity in several areas of the brain [5]. Clinical studies have demonstrated that 
an adjunct treatment by means of administration of estrogens, namely 17β-estradiol, resulted 
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in the enhancement of the symptomatology of the patient [6]. Some potential mechanisms 
have been proposed. However the precise mechanisms that explain estrogen‘s effects in 
Schizophrenia are still unclear. 
 
1.2. Objectives 
 
This thesis will investigate the effects of neurosteroids, estrogens and testosterone, and 
endocannabinoids in Schizophrenia, with the aim to identify potential novel therapeutic 
avenues. In order to achieve this objective, neurons were differentiated from induced 
pluripotent stem cells derived from healthy control males, providing a proper model system 
required for the study of this neurodevelopmental disorder. Using human iPSCs derived 
neurons, the protective effects of neurosteroids and endocannabinoids in Schizophrenia were 
investigated. 
 
1.3. Work structure 
 
The following document aims to cover the theoretical concepts explored during the thesis 
as well as to provide a full report of the project developed with the referred aims. Therefore 
the report will be divided into six chapters, including ―Chapter 1 – Introduction‖. The second 
chapter ―State of the art‖ will provide an overview about Neuroscience (brain structure, 
neuronal development and neuritogenesis), Schizophrenia as a neurodevelopmental disorder 
and the importance of dendrites and synapses; the role of Estrogens in the brain and 
influence on neuronal connectivity; the Endocannabinoid system; and Schizophrenia ―in a 
dish‖, where it is explored the use of hiPSCs as an in vitro model system to differentiate 
glutamatergic cortical neurons. Then in chapter three, ―Materials and Methods‖, the 
different methodologies used are described: Cell Culture, Immunocytochemistry, Image 
analysis and Statistical analysis. Moreover Chapter 4 exposes the results observed in the 
experiments, firstly reports the optimization experiments and then the Neurosteroids and 
endocannabinoids effects on neurite outgrowth. ―Chapter 5 – Discussion‖ will discuss the 
limitations of hiPSCs and drawbacks found during the development of the project and will 
debate on how the different treatments affected neural development. Finally, ―Chapter 6 – 
Conclusions‖ summarizes the information previously exposed. 
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  Chapter 2.
 State of the art 
2.1. Brain structure  
 
The human brain is the most complex and at the same time extraordinary organ in the 
human body, not only for the excitement of its unknown but for its fundamental role on the 
interplay of the different functions that contribute to the homeostasis of our body.   
This organ is protected by the skull, being suspended in cerebrospinal fluid and isolated 
from the bloodstream by the blood-brain-barrier. It is included in the central nervous system 
that comprises the brain stem (midbrain, pons and medulla oblongata), the spinal cord and 
finally the brain, which includes three major regions, the diencephalon (thalamus and 
hypothalamus), the cerebellum and the cerebrum/cerebral hemispheres, represented on 
figure 2.1.  
 
Figure 2.1. Central Nervous System, structural regions. Adapted from [7] 
 
The cerebrum regulates the most complex functions and sees its structure stratified in a 
thick outer layer, the cerebral cortex and three deeper layers, the basal ganglia, the 
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hippocampus and the amygdaloid nuclei. The basal ganglia associated to motor functions, the 
hippocampus to memory storage and the amygdaloid nuclei to emotions, involving autonomic 
and endocrine responses. 
The cerebral cortex is structurally divided in four lobes: frontal, temporal, parietal and 
occipital lobes, responsible for different functions. This structure can also be categorized 
based on the process complexity of the tasks, controlled by each region, as primary or 
association cortex, to perform basic motor or sensory functions or to associate different types 
of information to do more complex processing. In order to map the cerebral cortex with 
human behaviour, several approaches have been explored, from magnetic resonance imaging 
(MRI) and positron emission tomography (PET) in healthy volunteers, to mapping during brain 
surgery and insights from patients with lesions in specific areas of the cortex. The brain 
mapping has been evolving over the time and nowadays the four lobes that constitute the two 
cerebral hemispheres have specialized functions. The occipital lobe processes visual 
information; the parietal lobe is associated to somatosensory functions; the temporal lobe 
with hearing; and the frontal lobe is responsible to process motor functions, control 
movement and plan future actions.  
It is important to refer that sensory and motor functions present a contralateral action, 
motor information from one side of the brain lead to an action on the opposite side of the 
body, the same happens to sensory information (arriving from one side of the spinal cord will 
be processed on the opposite hemisphere of the cerebral cortex). Moreover despite the 
similarities of the two hemispheres, they are not completely symmetrical in structure nor in 
function. The anatomical structures of both left and right hemispheres can be observed on 
figure 2.2. 
 
 
 
Figure 2.2. Lateral and coronal view of the brain. Anatomic representation of the left hemisphere and 
respective lobes (left); coronal section of the brain (right) indicating the outer layer of the cerebrum, 
the cerebral cortex. Adapted from [7]. 
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2.2. Cerebral cortex and neuronal development 
 
The following topic will primarily focus on the formation of the different layers of the 
cerebral cortex to then explore the development of the neuronal structure, the different 
stages involved, namely the formation of the immature neurite into the single axon which is 
the first manifestation of neuron polarization.  
 
2.2.1. Cerebral cortex - layers 
 
The cerebral cortex presents an organized structure of 6 layers, characterized by the type 
of neuron and additional elements (figure 2.4), being numbered from the pial surface to the 
white matter (outer to deeper layers).  
Depending on the type of staining, the structures that define these layers can be 
identified. The Golgi stain allows the visualization of both dendrites and cell soma, whereas 
Nissl and Weigert stain only identify the cell soma and proximal dendrites, and axons 
(myelinated fibres) respectively.  
 
 
Figure 2.3. Six Layer structure of the cerebral cortex. 
 Adapted from [8]. 
 
  
The neurons distributed along the 
structure have been identified as 
projection neurons and local 
interneurons. Layers III, V and VI 
present projection neurons, 
characterized by a pyramidal shape cell 
body and the use of glutamate as a 
primary transmitter (excitatory 
aminoacid). Local interneurons are 
GABA-ergic neurons that make use of 
the inhibitory neurotransmitter amino-
butyric acid (GABA), being present in 
all layers and representing 20-25% of 
the total number of neurons.  
 
6  State of the art  
 
6 
 
The different layers represented on figure 2.3 have been termed not only by the type of 
neurons present but also by its extra constituent elements. The outer layer of the cerebral 
cortex, Layer I has been defined as molecular layer, consisting in dendrites of deeper cells 
and axons. Layer II, external granule cell layer contains granule cells (small spherical cells). 
As the previous, Layer III is also named according to its composition and position, as external 
pyramidal cell layer. Pyramidally shaped neurons are the type of neurons featured in this 
layer. Layer IV is defined as internal granule cell layer named by the presence of granule 
cells, as layer II. Layer V, as layer III contains pyramidally shaped neurons, glutamatergic 
neurons, as referred before. Therefore it is defined as internal pyramidal cell layer. At least 
the inner layer, Layer VI termed polymorphic or multiform layer is constituted by different 
types of neurons being the border of axons between to and from the cortex.  
Each layer of the cerebral cortex receives or sends information for different regions of the 
brain or the human body. The organization of the cerebral cortex in a stratified structure 
allows a higher performance and processing of information, increasing the efficiency of the 
inputs-outputs, which would not be expected on an unorganized frame.   
 
2.2.2. Neuritogenesis 
 
During neuronal development, a neuron forms two different types of processes, multiple 
dendrites and a single axon. Besides the morphological differences, these two different 
structures differ on the composition and structural components.  
The different stages that comprise this process have been documented using different 
neuronal cell types. The following study used rat embryonic hippocampal neurons, 
represented below on figure 2.4. 
 
 
Figure 2.4. Neuronal development. Morphological changes of rat embryonic hippocampal neurons 
in culture. At least 7 days are needed to reach stage 5. Adapted from [9]. 
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Immediately after being plated, little protrusions named lamellipodia attach the cell to 
the substratum, surrounding the cell and completing stage 1. Stage 2 is defined by the 
elongation of these little projections that are now defined as immature neurites, extending to 
a maximum length of approximately 20µm. At this point the neurite growing process is 
represented by neurite elongation and retraction, with no significant difference between 
neurites. After 24 hours, one of the neurites starts to elongate faster than the others that 
remain steady. This leads to the formation of the axon and the polarization of the cell, stage 
3. The following stage, stage 4, is marked by neurite maturation, which develop into 
dendrites along with axon elongation. Finally neuronal connectivity is possible with the 
formation of dendritic spines at stage 5 [10].  
 
2.3. Schizophrenia 
 
The society has been carrying the burden of mental disorders for centuries. Since the 
ancient ages, symptoms associated with psychiatric diseases have been terrifying human 
beings. Mental disorders such as Schizophrenia were previously associated to popular beliefs, 
or as a result of possession or gods‘ punishment for immoral behaviour. Schizophrenia 
symptomatology has been documented over the time, from the Stone Age until the present 
[11]. 
Besides the complexity of the disorder, the history of Schizophrenia is not linear. The 19th 
Century observed an emergence in mental health development, and in 1878 during studies 
with young adults suffering from dementia, Emil Kraepelin named the disorder as ―dementia 
praecox‖ (early dementia), characterized by a decline of cognitive process.  
However it was only in the 20th Century that Eugen Bleuler first defined the term 
―Schizophrenia‖. In 1911 Bleuler defined Schizophrenia as the four ―A’s‖, flattened Affect, 
Autism, impaired Association of ideas and Ambivalence [12]. Over the years researchers have 
attempted to classify the disorder but the complexity and unknown etiology of Schizophrenia 
causes a constant revision of the concept.  
Nowadays it is defined as a chronic, neurodevelopmental disorder affecting 1% of the 
world‘s population [13]. Schizophrenia is a syndrome, diagnosed by the clinical observation of 
the signs and symptoms of the patient, because of its unknown cause. 
 
2.3.1. Etiology and pathophysiology  
 
Schizophrenia is a heritable developmental disorder with an estimated heritability as high 
as 80% and it manifests in late adolescence or early adulthood with a higher lifetime risk of 
developing the disease for males than for females [14].  It is not only devastating for the 
patient that experience a lifetime of disability and emotional distress that in worst scenarios 
can lead to suicide (10%), but also for the family since these individuals are overrepresented 
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among homeless, unemployed, unmarried, socially isolated and chronically hospitalized. It is 
estimated that 40% of schizophrenics suffer from substance abuse, 20% are homeless and 10% 
commit suicide as previously referred [15]. 
Several approaches have been used to investigate Schizophrenia, although its aetiology is 
unknown. Pharmacological, magnetic resonance brain imaging and post-mortem studies have 
revealed a decrease in brain volume, aberrant neurotransmitter signaling, reduced dendritic 
arborization and impaired myelination in the brains of schizophrenic patients. 
Observations from brain imaging of first-episode patients registered decrease on the 
whole brain volume mainly in the gray matter of the hippocampus, basal ganglia and 
thalamus, and increased ventricular volume [16]. On chronically ill individuals the frontal and 
temporal gray matter areas of the cortex registered the most significant volume deficits, but 
whether the deficits are due to the disease or the long-term antipsychotic treatment remains 
unclear.   
Moreover functional MRI tests have detected cortical hyperactivity and hyperconnectivity 
between the cortex and hippocampus in SCZ patients at rest, in contrast to a reduced 
activation of the cortex during working memory tasks [15]. 
Despite the investigations that surround this disorder, its treatment is lacking since the 
aetiology and neurobiological systems that explain the disease remains poorly understood.  
The discovery of the psychosis-inducing effects of dopamine-releasing drugs, such as 
amphetamine, triggered the emergence of the ―dopamine (DA) hypothesis‖ of SCZD. This 
hypothesis proposes that an excessive activation of D2 receptors caused the positive 
symptoms of Schizophrenia. Anti-psychotics and later atypical anti-psychotics were 
introduced as a form of treatment since they allowed the blockage of the D2 dopamine 
receptor. This form of treatment focused on the dopamine hypothesis reduced the positive 
effects (delusions and hallucinations) but failed on the improvement of the cognitive deficits. 
Therefore more recently, the treatment of Schizophrenia has focused on the cognitive 
symptoms leading to the hypothesis of Schizophrenia as a ‖glutamate disorder‖ which 
explains that the cognitive deficits may result from the low activity of the NDMA receptor on 
GABA interneurons in the prefrontal cortex [13]. 
Therefore, in order to develop more effective treatments for Schizophrenia, it is 
important to understand the implications of the large number of genetic liabilities associated 
with Schizophrenia and the developmental pathways that are disrupted. 
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2.3.2. Diagnosis  
 
Schizophrenia is a devastating and disabling 
mental disorder affecting 1% of the world‘s 
population[17]. It affects the way people think, 
interact with others and connect to the world. This 
brain disorder is different from person to person 
and persists in cycles (relapse and remission 
phases), with psychosis as the hallmark of 
Schizophrenia.  
Self-portraits reflect people‘s inside, the way 
they think and connect to the world, which have 
been used by clinicians as a way to understand 
their patients, namely psychotic individuals. 
       Figure 2.5. Schizophrenic self- portrait  
       of a female 19 year old patient [18].  
 
The features detected in clinics which allow the diagnosis of Schizophrenia are divided 
into three categories, positive symptoms, negative symptoms and cognitive symptoms. 
However, positive symptoms comprise the most representative clinical feature used for the 
performance of the diagnosis.   
Positive symptoms, also referred as ―psychotic symptoms‖, include delusions (false 
beliefs), hallucinations, paranoia and psychosis, normally expressed as hearing voices; 
whereas negative symptoms comprises symptoms reflecting a disruption if normal emotions 
and behaviors, as flattened affect, impaired attention, social withdrawal, alogia (poverty in 
the amount of speech) and anhedonia (reduced capacity to experience pleasure) [14]. 
Cognitive impairment is expressed by deficits in attention, memory, planning and social-
emotional processing [19]. As well as negative symptoms, this last category is harder to 
recognize by clinicians. However they are considered to be a leading cause of the disorder.  
The diagnosis of Schizophrenia is performed trough a diagnostic criteria, since until now 
no pathogenic symptoms were found for an accurate diagnosis of the disorder. The criteria 
are fulfilled if the patient presents two of the following symptoms, according to DSM-5 
(Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)[20]: 
 Delusions 
 Hallucinations 
 Disorganized speech 
 Disorganized or catatonic behaviour 
 Negative symptoms 
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Moreover, delusions, hallucinations or disorganized speech must be one of the 
experienced symptoms; and continuous disturbances must be present for or least 6 months, 
having one month with active symptoms.  
 
 
2.3.3. Current Therapeutics 
 
Nowadays the etiology of Schizophrenia is still unclear and to be revealed. Therefore the 
treatments applied are based on the symptomatology of the patient. These include 
antipsychotic medication and psychosocial treatments that focus on eliminating the symptoms 
of the disease.  
The first generation antipsychotics also called typical antipsychotics are dopamine D2 
antagonists and include different drugs that exert also an effect on other receptors, such as 
serotonin type 2 (5-HT2), alpha1, histaminic, and muscarinic. This first class of antipsychotics 
present a high rate of extrapyramidal side effects (rigidity, bradykinesia, dystonias, tremor, 
and akathisia). [21] Chlorpromazine (Thorazine) was the first antipsychotic introduced in the 
treatment of SZ. [22] Moreover Haloperidol (Haldol), Perphenazine (Etrafon, Trilafon) and 
Fluphenazine (Prolixin) are some other typical antipsychotics commonly used to overtake the 
positive and negative symptoms.  
The second generation or atypical antipsychotics introduced on the 1990s helped to 
surpass the side effects caused by the first drugs designed. Despite being dopamine D2 
antagonists, present lower rates of extrapyramidal adverse effects. This class comprises 
several drugs, including Clozapine (Clozaril), Asenapine (Saphris), Iloperidone (Fanapt), 
Lurasidone (Latuda), Olanzapine (Zyprexa), Paliperidone (Invega), Quetiapine (Seroquel), 
Risperidone (Risperdal), Ziprasidone (Geodon) and Cariprazine (Vraylar). However they show 
higher rates of metabolic adverse effects and weight gain. 
Recently another class has been emerging, Serotonin-dopamine activity modulators 
(SDAMs), which embraces Aripiprazole (Abilify, Abilify Maintena, Aristada) and Brexpiprazole 
(Rexulti).  [21] These new forms of treatment approved by FDA in 2014 and 2015, 
respectively, are characterized to act as antagonist at 5-HT2A and noradrenaline alpha1B/2C 
receptors, and as partial agonist at 5-HT1A and dopamine D2 receptors. [21] 
Schizophrenia treatment with antipsychotics attenuates patients‘ positive and negative 
symptoms. It includes two main phases: an acute and a maintenance phase (life-long).  The 
first characterized by high doses, followed by a reduction of the dosage on the maintenance 
phase. A relapse requires the increase of the drug concentration, which is then reduced to 
the minimum required to prevent the experience of further episodes/relapses. Moreover 
different medications need to be tested in order to find the best treatment and dosage, since 
not all patients respond in the same way.  
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Despite the medication given to schizophrenic patients, different approaches are also 
used aiming the integration of these individuals in society and to live in community. 
Psychosocial treatments help schizophrenics with their everyday challenges that are mainly 
caused by the disease, such as difficulty with communication, self-care, work, and forming 
and keeping relationships.[22] Furthermore the understanding of family members about the 
disorder in order to help their loved one and to learn strategies and problem-solving skills is 
of extreme importance (family education), namely to help with the treatment and to avoid 
relapses.[22] As previously mentioned, nowadays, SZ treatment is focused on both positive 
and negative symptoms. Despite not being as perceptive as other symptoms (hallucinations 
and delusions), cognitive impairment interferes with the capacity to work, to socialize and to 
live independently. The cognitive remediation includes several forms of therapy such as 
cognitive rehabilitation, cognitive enhancement, or metacognitive therapy that work on the 
idea that the brain is plastic and that neurocircuitry can be improved.[23] Vocational 
rehabilitation and assertive community treatment represent another two models of 
intervention that help schizophrenic patients on fighting the disease.[23] 
 
2.3.4. Neurodevelopmental disorders 
 
Neurodevelopmental disorders, such as Schizophrenia, are caused by a wide range of 
factors, including biological (cellular and molecular), as well as environmental factors. These 
disorders share the fact that the disease onset occurs during the periods of ongoing 
maturation and development that results in alterations of the developing Central Nervous 
System (CNS) leading to an abnormal neural development and brain function.  The complex 
genetic etiologies and varying environmental effects that contribute to these disorders 
demand proper and relevant model systems to further the study of these diseases and for the 
development of therapeutics. The study of these mechanisms in patients or animal models is 
difficult because of its variety, but the use of cell-based models namely human cell-based can 
be ideal experimental paradigms to investigate the disease [1]. 
 
2.3.5. Candidate genes 
 
Twin and adoption studies have demonstrated a substantial familial aggregation in 
Schizophrenia.  For instance the risk of illness is higher in monozygotic twins than in 
dizygotic. However some studies have shown that the risk of developing the disorder is an 
interaction between environmental and genetic factors, for e.g. about 11% of twin studies 
indicate a strong environmental influence on the development of SCZD [24]. 
The current leading candidate genes of Schizophrenia encode proteins with a multifaceted 
role in the nervous system. Its structure is known for its complexity and the encoded proteins 
have extensive and complicated interactions with other molecules. There have been 
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innumerous investigations in order to identify the genetic risk factors for Schizophrenia, such 
as family based linkage studies, candidate gene association studies which consist of biological 
hypotheses that led to the discovery of rare variants such as 22q11.2 deletion [25] and a 
chromosomal translocation in chromosome 11 disrupting the DISC1 gene in a Scottish family 
[26]. 
On other hand genome wide association studies (GWAS) have made interesting progress on 
identifying alleles and genomic regions not previously associated with the illness. This 
powerful technique is a DNA-based, hypothesis-free method which analyses genetic variation 
between individuals in a large population, being capable of uncover single-nucleotide 
polymorphisms (SNPs), micro-deletions and copy number variations (CNVs) related to a 
particular condition [27]. 
Despite the inconsistent findings there are some candidate genes for Schizophrenia as 
neuregulin 1 (NRG1), disrupted-in-Schizophrenia 1 (DISC1), and dystrobrevin binding protein 1 
(DTNBP1). It is hoped that genome wide association studies will clarify the existing studies 
regarding the genetics of Schizophrenia.  
 
2.3.6. Importance of dendrites and synapses 
 
The complexity of neuronal network allows the performance of brain functions including 
cognitive behaviour, learning, memory and social behaviour. The communication of neurons 
in the neural circuitry is possible by dendrite morphogenesis which involves the development 
of dendrite branching, dendrite arbors and dendrite spines during neurodevelopment. Central 
nervous system diseases namely neurodevelopmental disorders (NDDs) such as Schizophrenia 
are characterized by the presence of neural circuitry defects that has been seen as a launch 
pad for novel therapeutics [28]. 
Dendrites play a key role in brain function, helping in the process of receiving information 
and to generate appropriate responses. During neurodevelopment and in adulthood the brain 
suffers different network alterations that highlight its plasticity and dynamics, such as 
changes in dendrite branching, spine number and morphology [29]. 
The number of dendrites and the pattern formed by their extension is intrinsically 
associated with the management and itinerary of the information in the nervous system. This 
information is processed by neuron-to-neuron communication through junctions called 
synapses. Since dendrite branching and synapse formation are essential in the structural and 
functional plasticity of the brain, defects in the neuronal circuits significantly contribute to 
structural and functional deficits observed in NDDs as Schizophrenia [30]. 
Neuroimaging and post-mortem studies have demonstrated a decrease in volume of 
cerebral cortex in schizophrenic patients [31]. Alterations in connectivity and in dorsolateral 
prefrontal cortex (DLPFC) involved with working memory tasks is evident in schizophrenic 
patients, which may explain the functional deficits in working memory suffered by these 
individuals, and supports the hypothesis of Schizophrenia as a disorder of altered 
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connectivity. However these alterations in neuronal circuitry and the reduction in brain 
volume are not attributed to a decrease in the total number of neurons but to abnormalities 
of pyramidal neurons including smaller somal volumes, decreased dendritic arbor size and 
branching and reduced dendritic spine density, represented below on figure 2.6 [32]. 
 
Figure 2.6. Cortical pyramidal neurons from normal (left) and schizophrenic subjects (right). 
Differences in soma volume (1), spine density (2), dendritic length (3) and presynaptic markers (4) [33]. 
 
The pathologies of DLPFC circuitry implicate different components. Pyramidal neurons 
that represent 75% of cortical neurons, interneurons, which comprise 25% and axons from 
neurons that project to the dorsolateral prefrontal cortex, neurons in the thalamus and from 
DA-containing neurons in the mesencephalon innervate targets in the DLPFC [34]. 
In DLPFC the spine loss occurs particularly in layer 3 pyramidal neurons (figure 2.7). Since 
the total number is not altered, the density reduction is explained by an increase of space 
between neurons, caused by lower axon terminals and spines per neuron.  
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Figure 2.7. Regions involved in neural circuitry disturbances in Schizophrenia. [34] 
 
The hypothesis of Schizophrenia as a neurodevelopmental disorder also supports these 
alterations in connectivity. Therefore the molecular mechanisms behind these abnormalities 
are under investigation, and have implicated the expression of proteins that regulate spine 
size and maintenance. The next page presents a table (table 2.1) that summarizes important 
factors involved in the regulation of dendritic morphogenesis, the function and its specific 
role. 
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Table 2.1. Regulation of dendritic morphogenesis by different factors/molecules. 
Factor Function Role in dendrite morphogenesis 
Secreted Factors, Cell Surface Receptors and Cell adhesion molecules 
BDNF Neurotrophic factor Increases dendrite branching [35] 
Reelin Extracellular matrix glycoprotein Increases  dendritogenesis [36] 
Wnt family Secreted glycoproteins Promotes dendrite complexity [37] 
Ephrins and Eph 
receptors 
Receptor tyrosine kinases and their 
ligands 
Promotes dendrite arborization [38] 
Semaphorins 
Secreted and transmembrane 
proteins 
Initial step of neuronal polarization and 
promotes the origin of dendrites, controls 
dendrite bifurcation and complexity of basal 
dendrites [39] 
Notch Cell surface receptor Promotes dendritic complexity[40] 
Cadherin-catenin cell 
adhesion complex 
Cell adhesion complex, participates 
in signalling and regulation of actin 
cytoskeleton 
N-cadherin, δ-catenin,p120ctn and β-
catenin promote dendritic branching[41] 
Synaptic Scaffolding Proteins And Regulators 
PSD95 
Postsynaptic density scaffolding 
protein 
Stop signal for proximal dendrite branching 
[42] 
Cypin 
Protein that binds to the PDZ 
domains of PSD-95 and decreases 
localization of PSD-95 at the 
postsynaptic density 
Promotes dendritic branching[43] 
LAP family of 
proteins 
Densin-180 and Erbin— postsynaptic 
density proteins 
Promotes dendritic branching (Shank, δ-
catenin)[44] 
Regulators of the cytoskeleton 
Rac/Rho/Cdc42 Small GTP binding proteins 
Activation of Rac and Cdc42 promote the 
extension of neurites, while activation of Rho 
mediates the retraction of neurites[45-47] 
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2.3.7. Dendritic spines 
 
As referred previously, dendritic spines are key interveners in the neuronal circuitry and 
communication neuron-to-neuron. Dysfunctions in these structures have been documented 
and linked to neurodevelopmental disorders. Therefore, the following topic introduces 
important notions about this structure, necessary for forward concepts and for a better 
understanding of its role in modulating connectivity.  
Dendritic spines are described as little protrusions presented along neuron‘s dendrites. 
These structures present a ―mushroom‖ shape, formed by a neck and followed by a spine 
head. The complexity of the post-synaptic density structure and its constituent elements are 
still being investigated. However, as represented on figure 2.8, is known  that dendritic 
spines are actin-rich, presenting at the post-synaptic density, neurotransmitter receptors as 
glutamate receptors, scaffold proteins (e.g. PSD-95) and signalling proteins as small GTPases.  
The cytoskeleton of dendritic spines is primarily composed of actin, allowing the dynamics 
of spines shape and size [48, 49]. Therefore changes in the actin cytoskeleton directly 
determine spine structure and morphology. Different stimuli and signalling pathways can be 
involved and induce the formation, elimination and alterations of these protrusions. A type of 
G-proteins involved in this regulation, are small-GTPases, which have the ability to regulate 
gene transcription and the dynamics of the cytoskeleton. Small-GTPases can be divided into 
five different families: Ras, Rho, Rab, Sar1/Arf and Ran; and binding to GDP and GTP regulate 
different cellular processes, according to the type of cell and small-GTPases family. Rho- and 
Ras- family are important candidates to control neuronal functions, by their ability to 
regulate cytoskeleton morphology and gene transcription [50]. 
 
Figure 2.8. Dendritic spines structure. (A) Cortical neuron expressing GFP (green fluorescence 
protein). Below a higher magnification of the dendritic spines is shown. (B) Immunofluorescence image 
of a dendrite cortical neuron stained for phalloidin (marker for β-actin) (C) Scheme representing a 
mature dendritic spine in contact with an axon. [49] 
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2.4. Estrogens 
 
The influence of steroid hormones, including estrogens have been object of innumerous 
studies, for having influence in a wide range of physiological functions, from reproduction to 
development and cardiovascular functions, to its activity in the nervous system. These 
compounds are a class of steroid hormones, of which 17β-estradiol is the most representative 
and biologically active form[50].  Estrogens have been reported to exert effects in different 
areas of the brain such as the hippocampus and cerebral cortex, modulating cognitive and 
memory functions in both animal models and humans.  
The following chapter will focus on estrogen role in the nervous system, the molecular 
mechanisms involved in its activity, the evidence of estrogens as a neurosteroid and 
neuromodulator and the resulting potential in treatment of psychiatric disorders as 
Schizophrenia.   
 
2.4.1. Role of estrogens in the 
cortex 
 
Despite our lack of understanding the precise 
molecular mechanisms that explain estrogen‘s effects 
on the synaptic plasticity, several findings have 
demonstrated estrogen‘s influence in different areas of 
the brain, modulating cognitive function within minutes 
to hours.  
Estrogen receptors ERα, ERβ and GPER1 (a G 
protein-coupled ER 1 or GPR30) are expressed in 
different areas of the brain, and are present in 
different cell-types, including neurons, astrocytes, 
oligodendrocytes and microglia (figure 2.9) [51]. ERs 
can be included in the nucleus, cytoplasm and 
membrane subtypes and may be associated with 
organelles (mitochondria, synaptic vesicles and 
dendritic spines) [51]. However it is important to note 
that GPER1 is an estrogen sensitive receptor and can be 
activated by multiple agonists, consequently having a 
more complex pharmacology.   
F
i
gure 2.9. Expression of ERs in         
different cell types. Adapted from 
[51]. 
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The ER subtypes are placed in distinct regions of the brain and lead to different responses 
in the neuronal circuitry. The expression of ERα is higher in the hypothalamus compared to 
ERβ, and is present in the mammalian forebrain. On the other hand ERβ is highly expressed in 
the cortex and hippocampus [50]. 
Classic estrogen receptors can be divided into two different subtypes, ERα and ERβ. The 
structure includes an N-terminal domain (defined as ―A/B domain‖), a conserved DNA-binding 
domain (with two Cys4 zinc fingers and defined as ―C domain‖), a C-terminal ligand-binding 
(the ―E domain‖) and finally a C-terminal (―F domain‖), figure 2.10. The subtypes present 
97% and 59% homology, at the DNA-binding domain and ligand-binding domain, respectively.  
 
 
Figure 2.10. Domain structure of the human ERα and ERβ estrogen receptors, and homology (%) 
between the two subtypes. Adapted from [52]. 
 
As previously mentioned, estrogens have been reported to exert actions in the brain. 
Several studies have documented the rapid influence on cognitive functions, which relies on 
cortical and PFC (prefrontal cortex) processes. For instance, the production of estrogens in 
the cortex of zebra finch song birds allowed social behaviours, and in rodent models, estrogen 
administration enhanced object recognition  [53, 54]. These studies highlight the potential 
application of estrogens in modulating cognitive symptoms in Schizophrenia. 
Moreover aromatase, an enzyme that converts androgens into estrogens, shows significant 
expression in response to stimuli in the hippocampus and cortex, in rodents, non-human 
primates and humans. The presence of this enzyme at pre-synaptic terminals places the 
synthesis of estrogens at the ideal location to act at the post-synaptic structures. Indeed, 
previous studies indicate that this ―de novo‖ synthesis of estrogens in the brain can enhance 
the modulation of neuronal connectivity, and that aromatase inhibition leads to a loss of 
dendritic spines in cultured cortical neurons [55]. 
 
2.4.2. Signalling cascades 
 
As explained in Chapter 2 (2.3.5. - Importance of dendrites and synapses), the 
communication and processing of information in the brain is performed through neuron-to-
neuron communication at synapses. These structures are manly located at dendritic spines, 
which may change their morphology in response to different stimuli (neuromodulators) and 
thereby lead to alterations of the neuronal network. Therefore, it is important to study the 
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mechanism underlying estrogen‘s effects on neuromodulation and synaptic plasticity and its 
potential use to as a therapy for neurodevelopmental disorders. The following chapter will 
then focus on the signalling cascades involved in estrogens action in the nervous system, in 
order to uncover the processes that underlie estrogens‘ activity.  
 
2.4.3. Rapid Modulation of neuronal connectivity 
 
Estrogen exerts its effects either by long-term actions or by a rapid modulation of 
neuronal connectivity. The canonical concept considers estrogens as endocrine signals, 
mediated by the regulation of gene transcription, resulting in long-term effects that can take 
hours to days to manifest. The study of the rapid modulation of neuronal connectivity has 
been increasing in recent years. These studies examine the involvement of estrogen receptors 
in intracellular signalling cascades in different areas of the brain, and hypothesize that ERs 
are located in or associated with the plasma membrane. The rapid activity of estrogens will 
be discussed in more detail, regarding their potential use as treatment in 
neurodevelopmental disorders, and as the key of this thesis.  
The rapid activation of membrane-signalling cascades can be triggered by estrogens either 
directly or by the transactivation of other receptors. It is still unknown which ERs activate 
this process and if its localization is integrated or associated with the plasma membrane. In 
order to address these questions, different studies have been performed.  
Several studies have implicated the rapid initiation of membrane-signalling pathways by 
17β-estradiol treatment of neurons, resulting in memory processing enhancement. The 
signalling pathways include the extracellular signal-regulated kinase (ERK) pathway, the 
phospholipase C (PLC) pathway, Protein kinase C (PKC), phosphatidylinositol 3-kinase 
(PI3K)/Akt or Protein kinase B (PKB) and Protein kinase A (PKA) pathway. The administration 
of 17β-estradiol in an ovariectomized young and middle age mice enhanced object 
recognition tasks, activating ERK1/2 and PI3K/Akt. The inhibition of these kinases resulted in 
no improvement of object recognition.  
Besides the classic ERs, ERα and ERβ and GPER1, some sensitive ERs have been 
documented, which may explain the different signalling profiles in varying brain regions 
activated by estrogens. This includes the cell surface signalling molecules ERX and STX-
sensitive Gq-membrane estrogen receptor (Gq-mER) [56]. Moreover, different isoforms of ERs 
can be expressed in different organelles within a cell, thus distinct signalling mechanisms may 
be activated [56, 57]. 
Regarding the localization of ERs, the use of membrane impermeable estrogen have 
supported the hypothesis of 17β-estradiol binding to the plasma membrane of neurons, and 
then initiating the signalling cascades. An example is the use of BSA-FITC-17β-estradiol, that 
resulted in an increase of Ca2+ levels and phosphorylation of ERK1/2, demonstrating the 
bonding to extracellular sites. Additionally, in ovariectomized mice 17β-estradiol activates 
ERK1/2 signalling resulting in the enhancement of object recognition. The binding of 17β-
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estradiol to the plasma membrane supports the presence of ER at the cell surface. However it 
is believed that the classic ERs, ERα and ERβ, do not contain hydrophobic residues/motifs 
that could enable its presence at the plasma membrane. As such, the capacity of these 
receptors to enable this localization is still unclear.  
At the membrane, ERs can modulate rapid signalling cascades directly or through other 
receptors. As shown in figure 2.11, several mechanisms are thought to be implicated in this 
process. The classic ERs, as represented below, are considered to interact with caveolin 
proteins and or with scaffold proteins, in order to initiate the membrane signalling cascades.  
 
 
Figure 2.11. Mechanisms involved in rapid estrogen modulation of membrane-signalling cascades 
[49]. 
 
ERα and ERβ have been demonstrated to couple with mGluRs (metabotropic glutamate 
receptors) independent of glutamate.  
A study using hippocampal neurons of female rats reported that after stimulation with 
17β-estradiol, ERα triggered mGlu1a signalling, leading to Gq-mediated stimulation of PLC, 
PKC and inositol triphosphate (IP3) and to ERK1/2 dependent CREB (cAMP response element-
binding protein) phosphorylation. ERα and mGlu1a interaction required the expression of 
caveolin-1. Moreover both ERα and ERβ activated mGlu2, decreasing Gi/o-coupled in cAMP, 
reducing L-type calcium channel-dependent CREB phosphorylation, which is essential for the 
expression of caveolin-3.The protein complexes formed by ERα and ERβ with caveolin-1 and 
mGlu1a, have been implicated in enhancing object recognition. Additionally GPER1 has been 
shown to be able to associate with other GPCRs, and to interact to TrKB receptors [58, 59]. 
The initiation of signalling cascades have also been documented to be triggered by ER 
association with scaffold proteins. The PELP1/MNAR, proline-, glutamic acid-, -leucine rich 
protein (PELP)1 or modulator of non-genomic actions of estrogen receptor (MNAR) have been 
shown to associate with ERα, ERβ as well as GPER1 to mediate membrane-signalling pathways  
[60]. These findings were shown in breast cancer cells and its role in neurons is still unclear. 
Another scaffold protein involved in membrane-signalling initiation by estrogens is striatin 
(also represented in figure 2.11). Striatin has been localized at the cortex and striatum 
(subcortical part of the forebrain), more specifically at the synapses [61]. It is expressed at 
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the dendritic spines, which binding to caveolin-1 may have influence in rapid ER induced 
signalling.  
The localization of GPER1 is controverisal. As a 7-transmembrane protein, some studies 
reported the localization of this receptor not only at the plasma membrane, but also at the 
Golgi apparatus, endoplasmic reticulum, mitochondrial membranes and microtubules [62, 63]. 
In order for GPER1 to initiate signalling, this GPCR couples to Gα and β/γ subunits (seen in 
figure 2.11 above) when localized either at the membrane or at intracellular sites, by 
activation of 17β-estradiol that has the ability to pass through the membrane.  
 
2.4.4. Estrogens modulation of dendritic spines 
 
Dendritic spines, as introduced in chapter 2.3.7 are believed to be involved in memory 
and cognitive function, being a key intervener in brain circuitry. This structure, in response to 
stimuli, suffers alterations in shape/size, being formed or eliminated, and resulting in 
changes of communication between neurons.  
The dynamics of dendritic spines, in response to estrogens, will be discussed below.  
Depending on the brain region that is being treated, it has been suggested that 17-β 
estradiol modulates dendritic spines by the activation of distinct signaling cascades. As 
mentioned previously, the presence of ERs varies from tissue to tissue. Therefore the 
regulation of dendritic spines by estrogen stimulus is dependent on the estrogen receptor that 
is present at the specific area of the brain. The use of ERβ-selective agonist (WAY-200070) in 
rat cortical neurons demonstrated a NMDAR-independent effect in the formation of dendritic 
spines, contrary to what happens with hippocampal neurons, which depend on NMDAR activity 
when propyl pyrazole (PPT, ER-α selective agonist) is applied.  
The increase in dendritic spine density by estrogen stimulation has been consistently 
documented. However it is still necessary to understand how the ERs are activated to lead to 
the modulation of the dendrites. Studies have revealed the involvement of 17-β estradiol in 
the spinogenesis modulation via distinct pathways, in both cortical and hippocampal neurons.  
 The stimulation of the dendritic spines of young cortical neurons has been linked to c-
SRC/Rac1/Cdk5/WAVE1/Arp2/3 pathway and a RhoA/ROCK-2/moesin cascade. In more 
mature cortical neurons, 17-β estradiol induced filipodia has been related to the signaling via 
Rap/ERK/AF-6 pathway. 
In hippocampal neurons spinogenesis by 17-β estradiol stimulation has been associated 
with the activation of p-LIMK/p-cofilin cascade that controls the polymerization of actin 
(thought to be performed via RhoA/ROCKdependent pathway).  
Several studies have documented estrogens effects in hippocampus and cortex of rat and 
mice models. It has been reported that when stimulated by 17-β estradiol, cortical neurons 
transiently increase their number in dendritic spines, returning to baseline levels after (30 
min in the cortex, and 2hours later in CA1 hippocampal neurons) [64, 65]. The newly formed 
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protrusions have been described to have a ―thin‖ morphology (figure 2.12) and to be 
functional [50]. Its functionality could be explained since an overlap with pre-synaptic 
terminals was detected, which in non-functional are absent (no synaptic connections are 
formed). 
Moreover, time-lapse images demonstrated that while the new formed spines resultant 
from the stimulus were preferentially eliminated at the end, pre-existent spines were not 
affected by 17-β estradiol, suggesting that the existent network is not affected [55]. 
Rapid activity dependent synaptic tuning has been implicated in the Long Term 
Potentiation (LTP) and Long Term Depression (LTD). [66] The rapid modulation of neuronal 
connectivity by 17-β estradiol has been shown to increase LTP, in particular. As described 
previously, the glutamate receptors AMPARs and NMDARs are essential in synaptic structure 
and plasticity.  
Srivastava and coworkers have demonstrated that an acute treatment of rat cortical 
neurons with 17-β estradiol resulted in a transient removal of GluA1-containing AMPARs and 
insertion of GluN1 containing NMDARs from synapses, returning to the initial state after 60 
min. [55] As represented on figure 2.12, this formation of ―silent synapses‖ is developed by 
deletion of AMPARS, which is implicated in the modulation of neural circuits. In hippocampal 
neurons 17-β estradiol exert actions by mediation of distinct pathways, which is explained by 
the different signaling mechanisms existent in the different cells.  
 
 
 
 
 
Figure 2.12. Transient increase in connectivity induced by 17-β estradiol stimulation [50]. 
 
Neuronal stimulation by estrogens seems to result in the formation, followed by 
elimination of transient spines, having almost no effects on pre-existing spines. It has been 
proposed that the rewiring of adult brain could be enhanced by strengthening existent 
synapses or by increasing the number of functional synaptic connections. Therefore the 
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question on how estrogens modulate and enhance neural function and cognition needs to be 
investigated further. 
 
2.5. Endocannabinoid system  
 
The endocannabinoid system is a neuromodulatory system that plays different roles in 
important physiological processes not only in the brain but also in other regions. This system 
has been associated to the pathophysiology of several diseases as neurodegenerative [67], 
psychiatric [68], stress-related conditions [69], pain and inflammation [70] and immunological 
disorders [71]. 
After being synthesised in response to different stimuli, endocannabinoids activate their 
specific targets and trigger biological responses depending on the cell type and tissue that are 
affecting [72]. The two types of cannabinoid receptors that have been identified so far are 
CB1R and CB2R [73, 74]. 
The endocannabinoid 2-Arachidonylglycerol, that will be referred as 2AG, is an agonist of 
the cannabinoid receptors CB1R and CB2R, and also activates the orphan receptor GPR55 [75]. 
The effects of these endocannabinoids in neurite outgrowth were studied, which can possibly 
suggest the presence of these receptors on hiPSC cortical neurons.  
 
2.5.1. Therapeutic potential 
 
Schizophrenia implicates genetic risk factors, involved in important developmental 
processes, from early stages to late stages of development. A prior knowledge of the risk 
genes, would mean that an effective treatment that targets the genetic predisposition 
disorder would be the best option. However this is not feasible at such an early stage of 
development. Therefore, a late stage of postnatal brain development (adolescence), where 
the brain is highly plastic and still in development is a more appealing phase to investigate 
novel therapeutics. The understanding of environmental stimuli allied with the genetic 
predisposition for the disorder would not only clarify its etiology and pathophysiology but 
would also help the development of new drugs.  
During adolescence, cannabis abuse has consistently been linked to Schizophrenia [76], 
namely on individuals with the genetic predisposition for the disorder. Despite being involved 
in important cellular processes such as neural progenitor proliferation, neuronal migration, 
and axonal growth, the endocannabinoid system has also been implicated on the regulation of 
neurotransmitter systems, including glutamatergic, GABAergic, and dopaminergic synaptic 
functions. [77] 
There is still some controversy regarding the acceptance of Schizophrenia has a 
dependent risk factor since the majority of individuals who consume cannabis to not develop 
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the disorder. Its use may contribute to the onset of SZ, however by itself does not lead to the 
development of Schizophrenia. Genetic risk factors, characteristic of the disorder, and/or 
other environmental risk factors need to be involved.  Moreover a functional polymorphism of 
catechol-O-methyltransferase (COMT) that encodes a major dopamine degradation enzyme 
has been identified and associated with the influence of cannabis in psychosis.[78] Adding to 
the information given by genetic studies, post-mortem, neuroimaging and cerebrospinal fluid 
(CSF) have shown the involvement of the endocannabinoid system in SZ. Post-mortem studies 
have reported an increase of the cannabinoid receptor, CB1R, in different brain regions, as 
the cerebral cortex. [79] Magnetic resonance imaging studies performed on either cannabis 
users or cannabis-exposed schizophrenic patients, have reported a reduction in brain volume 
in regions rich in CB1R. Furthermore it has been verified that the use of cannabis during 
adolescence leads to a greater volume loss than in post-adolescence. [80] 
Endocannabinoids regulate axon growth, coordinating a proper guidance and patterning 
for both GABAergic interneurons and pyramidal neurons during brain development. [81] The 
role of endocannabinoids in neuronal circuitry can be also observed on its influence in 
synaptic signalling. Endocannabinoids present a retrograde signalling function, by a 
suppression of neurotransmitters release at both excitatory and inhibitory synapses, via CB1R 
signalling. The release of endocannabinoids at post-synaptic regions is regulated by calcium 
influx with neuronal depolarization through different factors: NMDA receptor, voltage-
dependent calcium channels (VDCC), and calcium release from intracellular stores. [82] As 
mentioned above, CB1R, is expressed in several regions that control cognition and emotion 
(the hippocampus, amygdala, and cerebral cortex). The influence of the eCBs on synaptic 
plasticity has been reported in short-term depression and long-term depression, for instances. 
[77] Moreover a co-treatment with antipsychotics in rodents, using a CB1R receptor 
antagonist (AVE1625), revealed an improvement of cognitive function and reduction of typical 
antipsychotics side effects.[83] 
The eCBs plays important roles during brain development, namely at an embryonic and 
early stage. However it is at a postnatal phase that researchers have been focusing their 
attention in order to find new strategies to fight the disorder. This phase is targeted not only 
for being more practically feasible, but for being a critical period of plasticity and maturation 
of neurotransmitter systems and neuronal circuitry as a whole.  
Following a few studies are presented (table 2.2) in order to show the potentialities of the 
endocannabinoid system as a potential therapeutic avenue of several diseases, namely 
Schizophrenia.  
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Table 2.2 - Clinical trials showing the potentialities of the eCB system has a novel 
therapeutic avenue  
 
 
 
2.6. Schizophrenia ―in a dish‖ 
 
 
2.6.1. Stem cells  
 
Early in development, the fertilized egg that gives rise to the entire organism has the 
ability to differentiate into all cell types, a characteristic known as totipotency (from Latin 
totus – ―whole‖, ―entire‖ and potentia – ―ability‖, ―power‖). During development cells start 
to lose this ability, being labelled according to this capacity. 
Stem cells are unspecialized cells capable of rewiring or producing new stem cells 
(through mitosis) that according to the environment where are inserted can differentiate into 
specialized cells with specific functions. These cells can be divided in two types, embryonic 
stem cells and adult stem cells.  Embryonic stem cells are undifferentiated cells from a 3 to 
5-day embryo that can divide for a long period of time, being capable of developing the 
tissues of the three germinative layers (ecto, endo and mesoderme). An adult stem cell can 
be found in a mature tissue among differentiated cells, acting as a repair system for example 
during injury and in disease. However, not only are they present in a very small number, their 
Diagnosis Outcomes 
Schizophrenia 
CBD (Cannabidiol) enhanced anandamide signaling being as effective as amisulpride, a 
standard antipsychotic  [84] 
Schizophrenia Cannabis does not cause psychosis by itself [85] 
Bipolar disorders 
Cannabis use was associated with better neurocognitive function, but the opposite the 
opposite occurred for schizophrenia subjects. [86] 
Epilepsy 
50 % reduction in seizures by the use of oral cannabis extracts, in 1/3 of children 
presenting different forms of eppilepsy. [87] 
Cancer 
Cannabis use ―is perceived as highly effective‖ by some patients with advanced cancer. 
[88] 
26  State of the art  
 
26 
ability to differentiate is limited since they can only specialize into the cell types of the 
tissue where they reside.  
Pluripotent stem cells can differentiate into all cell types apart from cells of the amniotic 
sac and placenta, being present at the early stages of the embryo. Multipotent stem cells 
capacity to differentiate is limited, since they can only develop into a limited number of cell 
lines. 
Not so long ago researchers believed that after a cell differentiation into a specific cell 
type their ability to originate another type of cell was lost. The researcher Conrad Hal 
Waddington compared the development of an organism and specifically of a single cell to the 
fall of a ball by the slope of a mountain (figure 2.13). The journey performed by the cell 
resulted in its differentiation into a specific cell, and a different route would lead to the 
formation of another cell type.   
 
 
Figure 2.13. Conrad Hal Waddington comparison of the human body to a landscape [89]. 
 
2.6.2. Induced pluripotent stem cells (iPSCs) 
 
In 1962, the embryologist Jonh B. Gurdon contradicted the previous theory of cell 
development in one straight direction, by its beliefs that all cells contain the genetic 
information necessary for an organism to form. Exploring his hypothesis, this researcher 
eliminated the nucleus of a frog‘s egg and replaced it by the nucleus of a somatic cell 
(specialized cell), from the intestine of a tadpole. Contrarily to the predictions of many, his 
experiment resulted not only in the formation of a tadpole but in the generation of a full-
grown frog, demonstrating that the genetic material of mature cells have the same potential 
as embryonic cells. [90] 
After 40 years Shinya Yamanaka, by studying the pluripotency of embryonic stem cells, 
found out that only 4 genes were required for a somatic cell (fibroblast in the case of his 
experiment) to return to its initial pluripotency that enables the formation of all cell types. 
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Identifying the genes that encoded the transcription factors required for the pluripotency of 
embryonic stem cells, Yamanaka and coworkers were able to demonstrate that specialized 
cells could be reprogrammed into pluripotent cells, named induced pluripotent stem cells 
(iPSCs). Discovering the genes required for fibroblasts to become pluripotent (Oct3/4, Sox2, 
Klf4 and c-Myc), he introduced these genes in the cell by retroviral transduction. The iPSCs 
formed were then injected into mouse embryos, attesting their similarity to embryonic stem 
cells (ESCs) [91]. 
In 2012 Sir Jonh B.Gurdon, together with Shinya Yamanaka were awarded the Nobel Prize 
in Physiology or Medicine, ―for the discovery that mature cells can be reprogrammed to 
become pluripotent‖[92]. 
The iPSCs technique introduces a wide range of possibilities, not only negating the need 
for embryos in the generation of embryonic stem cells but also for providing the opportunity 
for each individual to have their own pluripotent stem cells (figure 2.14).  
 
 
 
 
Figure 2.14. Illustration of the iPSCs ability to differentiate into different cell types [89]. 
 
2.6.3. Human induced Pluripotent Stem Cells (hiPSCs) 
 
After Yamanaka discovery, the experiment was expanded to human cells, and in 2007, 
induced pluripotent stem cells were produced from a human fibroblast, leading to the 
generation of the first hiPSCs (human iPSCs) [93]. The hiPSCs were reprogramed from human 
somatic cells by transduction of the same transcription factors (Oct3/4, Sox2, Klf4 and c-Myc) 
used on the mouse somatic cells, hiPSCs are able to differentiate into the cell types of the 
three germ layers.  
Since then, numerous experiments have been performed to produce hiPSCs derived from 
mature adult cells of different cell types. Reprogramming somatic cells to iPSCs enabled 
innumerous applications, providing the opportunity to generate patient and disease-specific 
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stem cells to model human diseases, helping drug discovery, and enabling mechanistic 
studies. hiPSCs offer a new perspective of how things work without the drawbacks and ethical 
issues associated with the use of human embryonic stem cells, not to mention in the 
advantages of using the cells from the patient itself to study a certain condition.  
In order to understand the pathophysiology of different disorders, animal models are used 
to simulate human conditions. Depending on the disease, after reprogramming the somatic 
cell, the resulting hiPSCs can be differentiated into the desired cell lineage. 
Neurodevelopmental disorders have been studied for many years, but no significant 
advances in therapeutics have been achieved. Post-mortem studies have provided information 
regarding the abnormalities present in the brain circuitry, and animal models have helped to 
understand the mechanisms associated with the disease and the function of specific genes. 
However, the human brain features significant differences compared to rodents that result in 
cellular and molecular mechanisms different enough for the developed therapeutics not to be 
adequate for humans.  
Despite providing important information for the understanding of psychiatric disorders, 
the possibility of studying the development and function of live human neurons is by far more 
attractive and has more potential than any model that could be possibly used.  hiPSCs can be 
differentiated into neurons and glial cells, under appropriate growth factors and cell culture 
conditions for the study of neuronal development and function. Therefore with hiPSCs, it is 
possible to access patient‘s genetic information and elucidate the mutations associated with 
the disease and its severity. The differentiation of hiPSCs in neuronal progenitors can be 
achieved by the inhibition of the SMAD signalling pathway, which can be further 
differentiated into specific neuronal cells, such as pyramidal neurons, referred in the 2nd 
chapter as the most representative neurons in the cortex and the cells that will be used on 
the investigation of this thesis [94, 95]. 
 
 
2.6.3.1. Human neural development 
 
Neuronal differentiation of hiPSC represents the in vitro phenomena that occur in vivo 
during the development of the embryo, throughout neural induction. The following segment 
will clarify the stages of human neural development and in vitro differentiation creating a 
bridge between both processes.  
After being reprogrammed from somatic cell types, hiPSC demonstrates the pluripotency 
of the inner cell mass of the blastocyst. Therefore these cells have the ability to differentiate 
into the three germ layers, endo, meso and ectoderm.  
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In human neural development, neural induction is 
triggered when the ectoderm is stimulated by the 
notochord, structure formed between the endo 
and the ectoderm. Signals diffuse from the 
notochord into the ectoderm, now called neuro-
ectoderm, which  leads to the development of the 
neural plate and then to the entire nervous 
system. The remaining ectoderm forms the 
epidermis. The bone morphogenetic proteins 
(BMPs), Wnt and Fibroblast growth factor (FGF) 
signalling pathways are believed to be associated 
to neural induction.  
The neural plate progressively wraps itself 
forming the neural tube and the neural crest 
(neural plate borders) that will give origin to the 
peripheral nervous system. Morphogens as Wnts, 
FGFs, retinoic acid and Sonic Hedgehog (Shh) will 
allow the development and patterning of the 
primitive regions of the central nervous system: 
forebrain, midbrain, hindbrain and spinal cord.  
Figure 2.15. In  vitro   differentiation  
of    hiPSC     and      human     neural  
development,     analogy      between  
processes.  Adapted from [96] 
 
Neural induction can be achieved by dual inhibition of the SMAD signalling pathway that 
includes the BMP inhibition and TGFβ pathways. The differentiation of hiPSC into neuronal 
cells is therefore initiated by the induction of a neuroectoderm, and the formation of neural 
rosettes. Neural rosettes are morphological markers of neural differentiation, reminiscent of 
structures of the neural tube that present all properties of the neural plate [97]. Neural 
induction can be induced and differentiated into different populations of neural progenitors 
using various small molecule antagonists or endogenous inhibitors. The combination of several 
signals, specific to certain regions and cell types allows the differentiation into distinct 
neuronal cell types. However numerous limitations are associated to the direct differentiation 
of hiPSC, including cell culture of impure population of cells and differentiation efficiencies 
and divergences related to differentiation efficiencies, from protocol to protocol. 
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  Chapter 3.
 Materials and Methods 
3.1. Cell Culture 
 
3.1.1. hiPSC lines – reprogramming process 
 
In this study four cell lines, derived from two healthy volunteers (two clones each) 
were considered (table 3.1).  The hiPSC lines were generated and reprogrammed from 
keratinocytes of healthy volunteers, transduced by lentivirus expressing OCT4, SOX2, KLF4 
AND C-MYC [98]. Quality control assays were performed to demonstrate the pluripotency of 
the iPSC cell lines ensuring the quality of the new reprogrammed lines [99]. 
The iPSCs cell lines were maintained in E8 medium in an humidified chamber at 37ºC 
(5% O2, 5% CO2), on geltrex coated plates. Medium was replaced every day and cell colonies 
were split with versene every 3-7 days when reaching optimal density. HBSS was used to rinse 
wells before passage. Further details about the different reagents used can be consulted on 
the annexes.  
 
 
Table 3-1 - Cell lines included in the study. Control (CT) male (M) cell lines, M1 and M2. The last two 
digits identify the clone (e.g.: CT.M1 has two clones, CT.M1.11 and CT.M1.04 cell lines) 
 
 
 
 
 
 
 
CT.M1 CT.M2 
CT.M1.11 CT.M2.05 
CT.M1.04 CT.M2.42 
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3.1.2. Neuralization Protocol 
 
The four cell lines referred before on table 3.1 were differentiated for 30 days, involving 
three different stages as schematized on figure 3.1. 
Neuralization of hiPSC was induced by dual inhibition of the SMAD signalling pathway. 
Cells were introduced to neuralization medium 50% N2 (Life Technologies, 17502-048): 50% 
B27 (Life Technologies, 17504-044) supplemented with SMADi (1µM dorsomorphin + 10µM 
SB431542) for 7 days and incubated at 37°C (5% CO2; 20% O2).  
After formation of a uniform neuroepithelial sheet, reached at day 8, cells were carefully 
passaged (1:1) to 6 well plates in order to obtain large cell clusters. For this purpose cells 
were lifted using accutase, spun down (2x, 2min, 900rpm) and ressuspended in DMEM:F12, 
plated in N2:B27 only (no SMADi). Neuralization medium (N2:B27) was changed daily and cells 
were passaged at days 13 (np2) and 17 (np3), ascorbic acid (AA2P) was introduced from days 
13 (np12) onwards. Reaching 100 % confluence, cryopreservation of neural progenitor cells 
(NPCs) was conducted, creating a stock of NP cell lines. Cells were gently thawed, plated on 
geltrex coated plates and cultured in neuralization medium N2:B27 containing bFGF. Medium 
was changed daily and cell passaging was performed at least once a week (confluence   
100%). Terminal plating (day 20) was performed in poly-d-lysine (PDL) and laminin (2µg/cm2) 
on 24 well coated plates, in N2:B27 + bFGF medium.  NPCs were then cultured for the 
following 7 days in differentiation medium, B27 supplemented with DAPT and AA2P. The 
medium was finally changed to B27 and AA2P, with no differentiation stimuli to let cells grow 
until day 30/fixation.   
Further details regarding the reagents used during the procedure and the neuralization 
medium during differentiation can be found on tables 6.1, 6.2 and 6.3 of the annexes.  
 
Figure 3.1. Representation of the direct differentiation of iPSC to cortical neurons.  Three stages are 
involved. Neural induction is initiated at day 1 (D1), lasting for 7 more days. Neuronal progenitors are 
obtained on the second phase (D8 – D21). Terminal differentiation is initiated from D21 – D30. Np: 
neural passage. 
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3.1.3. Treatments 
 
 Cells were differentiated for 30 days. At day 29 of differentiation, neurons were 
treated for 24hours being fixed immediately after (day 30), figure 3.2. Cortical neurons were 
treated with 17β-estradiol (also defined as E2), three selective estrogen receptors agonists 
(PPT, WAY200070 and G1), testosterone and an endocannabinoid agonist (2AG), table 3.2. For 
each of the four cell lines, triplicates were performed (# EXPM1, # EXPM2 and # EXPM3 – ‗M‘ 
for Multiple cell lines). 
 
 
Table 3-2 - Final concentrations used in the treatments of the for cell lines at days 29. 
 
 
 
Figure 3.2. Time length of cortical differentiation. Cells are treated at day 29 (treatments 
summarized on table 3.2) and ICC (Immunocytochemistry) starts 24hours later (day30). 
 
 
3.2. Immunocytochemistry (ICC) 
 
At day 30 of differentiation, cortical neurons were fixed in 3.7% formaldehyde (w/v; 
in 4% sucrose in PBS) for 20 min. Cells were permeabilized and blocked for 2 hours using a 
blocking solution (2% goat serum, 0,1% Triton X-100 in PBS), and then incubated overnight 
with primary antibodies diluted in (2% goat serum in PBS). On the following day, cells were 
incubated with secondary antibody solution (2% goat serum in PBS) for 1hour and 5-10 minutes 
in DAPI (Sigma: D9542 w/v; made in PBS at 1:10‘000 dilution). Cells were washed twice in PBS 
and DABCO (1,4 diazobizyclo[2,2,2]octane) antifade solution was added to retard 
Treatment Concentration Company [Catalogue Nr.] 
17β – estradiol / E2 10nM SIGMA [ E8875] 
WAY 200070 10nM Tocrins Bioscience [3366] 
G1 10nM Tocrins Bioscience [3577] 
PPT 100nM Tocrins Bioscience [1426] 
Testosterone 2nM SIGMA [ T1875] 
2AG 1µM Tocrins Bioscience [1298] 
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photobleaching (see table 6.4 on the annexes for further information about the recipe). Table 
3.3 summarizes the antibodies used in the project. 
 
Table 3-3 – Primary (shaded) and secondary antibodies (below) used on ICC.  
Antibody target Type Host 
Species 
Dilution Company [Catalogue Nr.] 
Anti-MAP2 Polyclonal Chicken 1:1000 Abcam [ab92434] 
Phospho-Akt (Ser473)  Polyclonal Rabbit 1:200 Cell Signalling [Antibody #9271] 
Chicken Alexa Fluor®488 Goat 1:1000 Life technologies [A11039] 
Rabbit Alexa Fluor®568 Goat 1:750 Life technologies [A11036] 
 
 
3.3. Image analysis  
 
Images were captured using a 20x objective of a Zeiss Axiovert Fluorescence 
Microscope, 3 images were taken per condition. Neurite Outgrowth, an application of 
MetaMorph® Software (automated image analysis software) was utilized to study neurite 
outgrowth of cortical neurons under the effect of estrogens, testosterone and 2AG. Several 
features could be collected however only mean outgrowth per cell (µm/cell) and mean 
branches per cell (nr/cell) were considered. ImageJ 1.49 was used for additional image 
processing, whenever needed.  
 
3.4. Statistical analysis 
 
Raw data was initially studied and organized using Excel to then be statistically 
analysed with Graphpad Prism 6. Since more than two groups were being studied a one way 
analysis of variance (ANOVA) was performed using the Fisher‘s LSD method in order to 
individually compare the effects of each treatment to the control condition. This way each 
comparison stands alone and is not affected by the mean value of other conditions/groups.  
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  Chapter 4.
 Results  
4.1. Optimization Experiments  
 
 
In order to investigate the effects of estrogens, testosterone and 2AG in hiPSC derived 
forebrain/cortical neurons it was utilized the neuralization protocol briefly described before. 
However some aspects had to be improved to fulfil the aims defined and to overcome the 
challenges found on the way.  
hiPSCs are extremely sensible cells, namely because of the extended periods in vitro. The 
first issue related to cell culture not only of hiPSC but all type of cells, is contamination. The 
control and quality of the reagents used not to mention on the cell handling according to the 
established standard operating procedure (SOP) of the laboratory is of extreme importance, 
specially given the long time periods needed to obtain mature neurons. In order to avoid 
major issues as cell death, contamination, cell lifting it is important to have a safety and 
caution cell culture handling.  
A proper coating is essential and has influences on several aspects as: cell adhesion and 
cell clumping, and even cell death. Prior to terminal differentiation plates are coated with 
PDL and laminin as referred on Chapter 3. Preliminary experiments were resulting on the 
formation of cell clusters and agglomerates of cells, and leading to the detachment of the 
monolayer, and consequently cell death. This forced to an update of the protocol since no 
suitable results could be obtained in these conditions. Therefore two parameters were 
changed, the time of incubation of poly-d-lysine and the concentration used for the laminin 
coating. The alteration of the period of incubation to overnight for both reagents and a 
decrease on laminin concentration allowed the improvement of the results. The time of 
incubation of PDL used to promote the laminin adherence for the formation of a robust matrix 
for neuron attachment, was increased from 3 to 24 hours.  
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It is important to note that an half medium change was the ideal procedure since a 
complete change would expose cells and increase the force of suction that could potentially 
lead to cell lifting.  
Cell clumping was also influenced by the type of plate used. Cells tend to be sparser on a 
24 well plate than on a 96 well plate as figure 4.1 clearly exemplifies. Even after changing 
laminin concentration cells form clusters on the 96 well plates (figure 4.1 (A)), whereas on 
the 24 well plate (figure 4.1 (B)) cells are sparser and presented as single cells. 
 
 
Figure 4.1. Difference of cell density in two different types of plates. (A) 96 well plate and (B) 24 
well plate at day 29 of differentiation (CT.M1.11 cell line). Images taken with an EVOS® XL Core 
Microscope, 10x objective. Note: Scale bars were not available, which does not represent a problem 
since images were not taken to perform measurements but to have a record during in vitro 
differentiation.  
The image analysis using Neurite Outgrowth Software requires cell plating at a low cell 
density since cells are traced individually. This parameter was improved gradually, having the 
best results (lower cell density) at the end of the project. An optimization of cell density also 
represented a challenge since the established protocol did not include cell counting. Cell 
density was controlled based on supporting documents [100] and on the volume of cell 
medium used to resuspend cells. Figure 4.2 illustrates how cell density was optimized along 
the different experiments. #EXPM1, #EXP M2 and #EXP M3 were performed in different time 
points, showing a decrease in cell density as the protocol was being upgraded.  
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Figure 4.2. Cell density optimization. A decrease in cell density is observed along the 
experiments. Figures A, B and C are representative images of CT.M2.42 cell line of experiments #EXP 
M1, #EXP M2 and #EXP M3 respectively. Images taken with Zeiss Axiovert Fluorescence Microscope. Scale 
bars 50µm (A, B and C). 
 
4.2. Image Analysis – MetaMorph 
 
 After taking a minimum number of 3 images per condition, the MetaMorph application 
Neurite Outgrowth provided segmented images and numerical results defining the morphology 
of the neurons concerning both cell bodies and neurites. 
 The application enabled the isolation of the cell bodies and identification of the 
neurites, based on the contents and wavelengths of the images. For this analysis two images 
were needed, the image containing the cell bodies and attached neurites (neurons) and 
images containing the stained nuclei. Images containing information regarding both cell 
bodies and neurites will be from now on referred as ―MAP2 images‖ and nuclei images as 
―DAPI images‖. 
 The isolation of the entire neurons is possible only with the information of the MAP2 
image. However adding the use of the DAPI image provides a higher accuracy since it allows 
the correlation of the stained nuclei with the cell bodies of the MAP2 image. It enables a one 
to one correlation between cell bodies and nuclei.  
  MAP2 + DAPI   MAP2 + DAPI 
  MAP2 + DAPI 
A B 
C 
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 In order to segment each image it is needed to set up setting values suitable to the 
image content (morphology of the features and intensity of the pixels). Working on the MAP2 
image these settings enable to specify threshold values to separate the cell bodies from the 
background and establish dimensions of the cell bodies and neurites.  Prior to segmentation, 
images are calibrated and background subtraction (statistical correction) is performed. For 
each experiment (#EXP M1, EXP M2 and #EXP M3), which includes the four cell lines referred 
previously, default settings were optimized and held constant. The resulting images 
represented on figure 4.4 not only help on the calibration of the settings, obtained through 
the analysis of multiple sample images, but also how the different cell lines behave on each 
experiment and between experiments.  
The physical characteristics of the traced neurons (figure 4.4) were plotted on an Excel 
file. However only two parameters were studied, mean outgrowth and mean branches.  
Mean outgrowth (µm/cell) is calculated by the average of the total neurite length, 
skeletonized outgrowth corrected for diagonal lengths, per cell. The mean branches per cell 
correspond to the total number of branch points/branching junctions by the number of cells 
present on the resulting traced image (positive cell body/nuclei). The different neuronal 
structures are represented on figure 4.3 for a better understanding of the defined 
parameters.  
 
 
 
 
 
Figure 4.3. Neuronal primary structures.  Nucleus, cell body, neurite and branch point physical 
characteristics can be found. 
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Figure 4.4. Segmented images after process and analysis with NeuriteOutgrowth. Four cell lines 
were used (CT.M2.42, CTM2.05, CT.M1.11 and CT.M1.04), having three replicates (#EXP M1, #EXP M2 
and #EXP M3). Images taken with a 20x objective using a Zeiss Axiovert Fluorescence Microscope. 
 
4.3. Neurosteroids and endocannabinoid effects 
on neurite outgrowth 
 
The neuralization protocol used enables the differentiation of hiPSC into 
forebrain/cortical neurons, as previously reported [96, 99]. After formation of a monolayer of 
neuroepithelial cells induced by SMAD inhibition, structures named neural rosettes form, 
presenting the apical-basal polarity of hNPCs. These structures have been identified 
previously by the expression of ZO-1 in the apical lumen and nestin positive cells on the 
surroundings [99]. 
In this dissertation the expression of these markers was not tested. However the typical 
rosette structure of the neural progenitors of the cell lines was confirmed during cell culture 
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of the NPCs. Figure 4.5. illustrates the neural progenitor cells (neural passage 10) prior to the 
last stage of differentiation.  As in vivo, neural stem cells polarize in a 2D structure in order 
to obtain the neural tube structure as referred before on Chapter 2 (2.6.3.1 - Human Neural 
Development).  
 
 
Figure 4.5. Rosette structure of neural progenitors. The cell line CT.M1.11 illustrates the 
morphologic characteristics of the cortical neural progenitors. Arrows point to the typical rosette 
structure of these cells. (A) This radial pattern is present in the all image. (B) Magnification of a section 
of image A, allows a closer analysis of the NPCs in culture before being terminally plated. Images were 
taken with an EVOS® XL Core Microscope (10x objective) during cell culture. Note: Scale bars were not 
available, which does not represent a problem since images were not taken to perform measurements 
but to have a record during in vitro differentiation. 
 
After 30 days of differentiation forebrain/cortical neurons were generated. Forebrain 
consists of both glutamatergic and GABAergic interneurons that can be differentiated from 
hiPSCs using different inductive signals [101, 102]. However the established protocol in our 
lab is focused on the differentiation of hiPSCs in glutamatergic projection neurons for being 
the most representative neuron cell type in the cerebral cortex.  On the following page, 
figure 4.6, shows the unipolar pyramidal morphology that characterizes this cell type and 
distinguishes from the multipolar morphology that interneurons present, as referred before on 
Chapter 2 (2.2.1 – Cerebral Cortex Layers). 
Estrogens, testosterone and endocannabinoids have been associated to affect 
neuritogenis of different neuronal cell types by activation of distinct signalling pathways [5, 
103, 104]. However up to now the study of its effects on the morphology of hiPSCs derived 
cortical neurons that attest the response of these cells to the referred treatments has been 
poorly documented [96]. 
 
A 
B 
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Figure 4.6. Unipolar pyramidal structure of glutamatergic cortical neurons. hiPSCs neurons 
differentiated for 30 days; MAP2 positive (green) and stained for DAPI (blue). Young immature neurons 
presenting an unipolar pyramidal morphology, poor in neurite ramifications. Images taken with Zeiss 
Axiovert Fluorescence Microscope. Scale bar 25µm. 
 
 
Each hiPSCs cell line was differentiated for 30 days leading to the generation of cortical 
pyramidal neurons. This experiment was repeated three times (Experiments M1, M2 and M3) 
knowing that per experiment four cell lines were differentiated simultaneously.  
In this dissertation, the influence of estrogens, testosterone and 2AG in neural 
development was studied after an acute treatment of 24 hours, at day 29 of differentiation. 
Neurite outgrowth was evaluated using MetaMorph and according to two parameters, mean 
neurite length (µm/cell) and mean branches per cell (nr/cell). The mean values of both 
parameters were normalized to the mean of the control condition of each experiment, i.e. 
the average of each condition was divided by the average of the control, per experiment. The 
following pages will explore the results of the three experiments performed for each cell line. 
Figure 4.7 plots the results of CT.M2.42 cell line, showing the influence of the different 
treatments compared to the control. Despite the disparities between experiments possibly 
caused by a number of factors as cell density, referred before (Chapter 4 (4.1- Optimization 
Experiments)), it is possible to observe an increase in neurite length (figure 4.7 (A)) in the 
presence of E2 (EXP M1), PPT and 2AG (EXP M2), and 2AG (EXP M3). Positive effects of these 
conditions in the number of branches per cell (figure 4.7 (B)), enhances the results of the 
previous parameter and the effect of E2, PPT and 2AG on neurite development.  
As it has been referred the three experiments were executed for each cell line. 
Regarding CT.M2.05, the results obtained for both parameters consistently show an influence 
of the ER-β agonist (WAY 200070) on neuronal development, measured not only on neurite 
length (figure 4.8 (A)) but also on the number of branch junctions per cell (figure 4.8 (B)), 
observed on EXP M3.  
  MAP2 + DAPI 
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CT.M1.11, a clone derived from another patient (M1), did not show any statistical 
significant results, neither on neurite outgrowth (figure 4.9 (A)) nor on the number of 
branches per cell (figure 4.9 (B)), relative to the control. 
Finally CT.M1.04 responds to the presence of PPT, agonist of the estrogen receptor ER-α, 
by a positive effect on the number of neurite branch points per cell (figure 4.10 (B)), 
expressed on EXP M2. Moreover, an increase of the neurite length relatively to the control 
shows the response of this cell line to the endocannabinoid 2AG (EXP M3). 
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Figure 4.7. Effects of the different treatments on neurite outgrowth (A) and number of 
branches per cell (B) on CT.M2.42 cell line. Treatments with 17β – estradiol (E2) on experiment M1 
and treatment with PPT and 2AG on Experiment 2, leads to an increase of neurite outgrowth relatively 
to the control (vehicle-treated cells) of CT.M2.42 cell line. 24h treatments with PPT AND 2AG resulted 
on a significant increase on the number of branches per cell. Quantitative analysis of the total neurite 
length by the total number of neurons; and analysis of the total number of branches by the total number 
of neurons; values of each experiments M1, M2 and M3 were normalized to the respectively control 
mean value (mean ± SEM). An one-way ANOVA, with Fisher LSD method was performed, * represents 
statistical significance of each group treatment relatively to the control.* p < 0.05; ** p <0.005. 
Experiment M1, N = [110 ; 214] cells; Experiment M2, N = [16 ; 57] cells; Experiment M3, N = [22 ; 68] 
cells. 
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Figure 4.8. Effects of the different treatments on neurite outgrowth (A) and number of 
branches per cell (B) on CT.M2.05 cell line. 24h treatment with WAY200070 (ERβ agonist) resulted on 
a significant increase on both neurite length (A) and number of branches per cell (B). Quantitative 
analysis of the total neurite length by the total number of neurons; and analysis of the total number of 
branches by the total number of neurons; values of each experiments M1, M2 and M3 were normalized to 
the respectively control mean value (mean   SEM). An one-way ANOVA, with Fisher LSD method was 
performed, * represents statistical significance of each group treatment relatively to the control.* p < 
0.05; ** p <0.005. Experiment M1, N = [128; 242] cells; Experiment M2, N = [15; 76] cells; Experiment 
M3, N = [12 ; 59] cells.  
 
  
43 
 
 
 
 
 
C T E 2 P P T W A Y  G 1 2 A G T E S T
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
C T .M 1 .1 1
N
e
u
r
it
e
 o
u
tg
r
o
w
th
 (
µ
m
/c
e
ll
) 
n
o
r
m
a
li
z
e
d
 t
o
 C
T
E X P  M 1
E X P  M 2
E X P  M 3
A
 
 
 
 
C T E 2 P P T W A Y  G 1 2 A G T E S T
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
C T .M 1 .1 1
B
r
a
n
c
h
e
s
 (
n
r
/c
e
ll
) 
n
o
r
m
a
li
z
e
d
 t
o
 C
T
E X P  M 1
E X P  M 2
E X P  M 3
B
 
Figure 4.9. Effects of the different treatments on neurite outgrowth (A) and number of 
branches per cell (B) on CT.M1.11 cell line. The treatments performed at day 29 of differentiation did 
not show statistical significance between experiments. Normalized mean values are similar or even 
lower than the control condition. Quantitative analysis of the total neurite length by the total number 
of neurons; and analysis of the total number of branches by the total number of neurons; values of each 
experiments M1, M2 and M3 were normalized to the respectively control mean value (mean   SEM). An 
one-way ANOVA, with Fisher LSD method was performed, p < 0.05; ** p <0.005. Experiment M1, N = [68 ; 
232] cells; Experiment M2, N = [22 ; 70] cells; Experiment M3, N = [1 ; 18] cells. 
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Figure 4.10. Effects of the different treatments on neurite outgrowth (A) and number of 
branches per cell (B) on CT.M1.04 cell line. The endocannabinoid 2AG influences neurite outgrowth 
(A) (EXP M3); neurite branching (EXP M2) (B) increases with the treatment with the ERα agonist PPT, and 
a negative effect is verified for the ERβ agonist WAY. Quantitative analysis of the total neurite length by 
the total number of neurons; and analysis of the total number of branches by the total number of 
neurons; values of each experiments M1, M2 and M3 were normalized to the respectively control mean 
value (mean   SEM). An one-way ANOVA, with Fisher LSD method was performed, * represents statistical 
significance of each group treatment relatively to the control.* p < 0.05; ** p <0.005. Experiment M1, N 
= [54 ; 210] cells; Experiment M2, N = [23 ; 106] cells; Experiment M3, N = [22 ; 65] cells. 
 
 
Under the conditions used in this study, cells respond mainly to the treatments 
summarized on table 4.1. The positive response to estradiol, which binds non-specifically to 
the classical estrogen receptors, ER α and ERβ, and GPER1, and response to PPT and WAY, ER 
α and ERβ specific estrogen receptors agonists, suggest that these cells express both estrogen 
receptors α and β. Moreover, despite the limitations associated to inter- and intra-patient 
variability and differences in cell density between experiments, the endocannabinoid 2AG 
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(agonist of CB1, CB2 and GPR55 cannabinoid receptors) increased neurite outgrowth and 
neurite branching in two cell lines (CT.M2.42 and CT.M1.04, clones of distinct patients), and 
twice on the same cell line (EXP M2 and EXP M3, CT.M2.42). These results suggest the 
presence of CB1 or/and CB2 receptors on young differentiated cortical neurons.  
 
 
Table 4.1 - Summary of the treatments considered statistically significant (one-way 
ANOVA, with Fisher LSD method). A negative effect (-) is also represented, meaning a 
decrease in neurite outgrowth and nr of branches per cell, relatively to the control condition. 
Experiment 
 
Cell line 
Experiment M1 Experiment M2 Experiment M3 
CT.M2.42 E2 
PPT 
2AG 
2AG 
CT.M2.05 - - WAY 
CT.M1.11 - - - 
CT.M1.04 (-) WAY PPT 2AG 
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  Chapter 5.
 Discussion 
5.1. Neurosteroids effect on neurite outgrowth 
 
The results support the notion of estradiol as a neurotrophic factor, in the way that 
regulates neurite outgrowth during neuritogenis and differentiation of cortical glutamatergic 
hiPSC derived neurons.   
Steroid hormones influence the nervous system having the ability to affect cognition as it 
has been studied over the time. Some controversy regarding positive and negative symptoms 
caused by estrogen therapy have been discussed in the area. A study in 2003 of Women‘s 
Health Initiative (WHI) of a long treatment with conjugated equine estradiol and 
medroxyprogesterone in post-menopausal women over 65 years, reported a decrease in 
cognitive function along with risk of dementia and stroke [105]. However, this controversy 
between studies, reporting opposite effects caused by estrogens has been attributed to the 
fact that human female brain is responsive to estrogens till a certain time, existing an 
―window of opportunity‖ [106] following menopause till when the hormone can exert positive 
effects, after this stage estrogen treatment leads to negative effects. 
Despite the adverse effects pointed to this hormonal treatment, as cardiovascular 
problems, stroke and risk of developing cancer [105, 107, 108], several positive effects have 
been reported suggesting the potentialities of estrogens as a therapeutic avenue for the 
treatment of several neurodevelopmental disorders  as Schizophrenia [109]. A recent study by 
Weickert et al., using raloxifene, a selective estrogen receptor modulator (SERM) 
synthetically synthesized, demonstrated the enhancing effects of estrogens over cognition in 
both human male and female. In this controlled-placebo study it was tested whether oral 
administration of raloxifene (120mg) of young middle-aged men and women with 
Schizophrenia add an impact on cognition improving the symptoms of the disorder, comparing 
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to the placebo. The adjunctive treatment of this SERM demonstrated improvements on 
attention/processing speed and memory in both genders. Moreover a transdermal treatment 
of 8 weeks with 17-β estradiol (200µg and 100µg) showed the enhancement of positive and 
negative symptoms of female schizophrenic patients relatively to placebo, having a better 
performance at 200 µg than 100 µg relatively to the placebo, in a large-scale randomized-
controlled trial [6].  
Human post-mortem studies and genetically-modified organisms have been used to clarify 
the cellular and molecular mechanisms that address the effects of estrogens in the human 
brain. Post-mortem studies have the inherent limitation of being a non-living tissue, not 
providing the full picture of estrogens effect namely during development. In the other hand 
animal models do not fully recapitulate the pathophysiology and the genetic complexity of 
the human brain. However is the use of animal models that has been the main source of 
information of estrogens neuroprotective actions. 
Studies involving animal models, either in vitro or in vivo, have reported the enhancing 
effects of estrogens, namely 17-β estradiol, in learning and memory, as well as in behavioural 
tests. 17-β estradiol influence over cognition has been associated to the ability of this 
hormone to modulate neural circuits, influencing the formation of neuronal processes, 
dendrites and axons, as well as dendritic spines and synapses [103, 110].  
Multiple studies have demonstrated a time- and dose- dependent response to estrogen 
treatment, having a critical time and concentration on which the positive response to the 
therapeutics is optimal.  Several studies using ovariectomized (OVX) female rodents have 
demonstrated impaired performance in working memory and spatial navigation, able to be 
reversed by acute treatment with 17β-estradiol. Luitne et al., performing an acute treatment 
30 minutes prior and post-training on OVX female rats, showed an enhancement on memory 
acquisition and consolidation [111]. In the same study, the administration of 17β-estradiol 2 
hours post-training did not reflected any effect, revealing that estrogens have a specific time 
frame of action to induce positive effects. The same was verified in an acute treatment of 
OVX rats performed immediately post-training with the selective agonist receptors ERα and 
ERβ, PPT and DPN, that did not exert an effect when performed 60 minutes after.  This time 
dependent response to estrogen treatment suggests that estrogens enhance cognition in a 
rapid and transient way as proposed before [112].  
In regards to the dose/concentration of administration, it is important to highlight the 
behaviour assumed by estrogen treatment. It has been proposed that estrogens assume an 
inverted U-shaped dose response curve, suggesting that there is an optimal dose where 
estrogens are most effective [111, 112]. 
Previous studies, using neural stem cells (hNSCs) or neural progenitor cells hNPCs have 
studied the expression of the different estrogen receptors and consequent effect in cellular 
function, showing estrogenic influence not only on proliferation but also on differentiation in 
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the human brain. hNPCs derived from fetal cortex were reported to be affected by a time- 
and dose- dependent 17β-estradiol treatment, increasing proliferation [113]. It was also 
addressed the expression of the estrogen receptors, ERα and ERβ, revealing an enhancing 
response to ERβ over ERα, mediated via a MEK/ERK1/2-dependent pathway [113]. The 
expression of ERs on hNSCs derived from fetal mesencephalic tissue and a dose dependent 
response to 17β-estradiol treatment following in vitro differentiation was also demonstrated. 
Moreover the use of hESCs has also been showing the influence of ERs activation in neural 
development, demonstrating an higher expression for ERβ over ERα in neurons differentiated 
from hESCs lines [114]. Furthermore in order to understand the influence of 17β-estradiol and 
of each estrogen receptor, Ca 2+ oscillations were analysed demonstrating the rapid action of 
17β-estradiol and a higher activation of ERβ, capable of changing Ca 2+ signalling [114].  
The use of iPSC technology as a model to understand estrogens effects in human neural 
development it‘s still in its preliminary stages. Recently Shum et al. (2015), demonstrated 
that hiPSC derived cortical neurons are responsive to estrogenic treatment. hiPSC derived 
neurons were differentiated for 35 days, being treated with 17β-estradiol for 24 hours at day 
34. A positive response on dendritic branching was observed, relatively to the control, 
showing the ability of estrogens to alter neuronal structure [96]. These results are consistent 
with what it is observed on the current dissertation, morphologic alterations in 17β-estradiol 
treated neurons (24 hours at day 29), represented by an increase in neurite length/cell which 
is also corroborated by the increasing number of neurite branches.  
The data presented here also suggests the expression of the classic estrogen receptors 
ERα and ERβ, revealed by the increasing values of the two studied parameters relatively to 
the control. This was shown performing a 24 hour treatment at day 29 of differentiation, 
using 17β-estradiol and also the specific receptor agonists PPT, WAY and G1. As agonists of 
the classic estrogen receptors (ERα and ERβ), PPT and WAY activated estrogenic signalling, as 
demonstrated by previous studies already referred. However there is still some controversy 
regarding the expression of ERβ over ERα [114]. Moreover the expression of GPR1, activated 
by the agonist G1, was not significant when compared to the control following a 24 hour 
treatment of hiPSC derived cortical neurons. A couple of reasons can be pointed to the 
response to G1 treatment. As referred before, estrogen treatment is dose- and time- 
dependent, presenting an inverted U shape dose response. Therefore two different reasons 
can be suggested, the dose used was not adequate and different concentrations have to be 
tested to find the optimal concentration where GPR1 is expressed; or since estrogens actions 
are rapid and transient, the neurite outgrowth analysis of 24h treated neurons could have 
failed the time point that this receptor activation was stimulating neuritogenesis. In order to 
discard this hypothesis different time points should be tested and mRNA and protein analysis 
should be performed to further verify the presence of this receptor.  
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Estradiol synthesis occurs mainly in the ovary, but it is also produced in other tissues as 
bone, adipose and nervous system not only in females but also in males [5]. The synthesis 
within the brain, independent from the peripheral steroidogenesis, allows the modulation of 
several neurobiological processes. Estradiol/17β-estradiol synthesis involves mainly two 
phases [5], the first in the mitochondria that leads to the conversion from cholesterol to 
pregnenolone, and the second in the endoplasmatic reticulum, that ends with the catalysis of 
testosterone into estradiol by the enzyme aromatase. Three different sources of estradiol 
have been suggested: peripheral estrogens, produced and circulating outside the nervous 
system; androgens (estrogen precursors) localized in the nervous system; and local synthesis 
from cholesterol [112].  
It has been reported that nanomolar concentrations of estradiol are required to induce 
rapid cellular and molecular responses, which is not verified in the plasma that presents low 
picomolar levels of this steroid [115]. In order to produce rapid responses, androgens, as 
testosterone, or cholesterol are proposed as estradiol main sources [112]. 
As an estrogen precursor, testosterone could have possibly triggered estradiol synthesis 
and influence the morphology of the differentiated glutamatergic cortical neurons. Despite 
having higher levels of neurite outgrowth and neurite branching relatively to the control, 
observed in some cell lines, the 24 hour testosterone treatment did not reveal statistically 
significant results. This could have been possibly due to the variability between experiments 
and cell lines, related not only to the limitations intrinsic to the use of iPSC technology, but 
also to the differences of cell density observed between experiments.   
The regulation of neuritogenesis (see Chapter 2 (2.2.2 - Neuritogenesis), for further 
details about this stage) by estradiol and the mechanisms involved in this process are still not 
clearly understood. Depending on the brain region and neuronal cell type, different 
mechanisms may be involved and influence the different stages of neuronal development that 
include axogenesis, dendritogenesis, spinogenesis and synaptogenesis.  
Arevalo et al., provided important insights on the molecular basis of estrogen regulation 
of neuritogenesis, which has been suggested to involve different signalling pathways. The 
initiation of MAPK cascade trough the activation of the signalling kinase Ras has been 
reported to influence neuronal development, which is activated by estradiol phosphorylation 
of c-SRC [103, 116]. Moreover, activation of the protein kinase C by estradiol [117] and 
increased levels of Ca2+ have also been associated to the regulation of this signalling cascade 
and posterior activation of the transcriptor factor c-AMP response element binding (CREB). 
Adding to this estradiol interacts with other factors such as the insulin-like growth factor-I 
(IGF-I) and the brain derived neurothropic factor (BDNF), interveners in neuronal 
development. IGF-I an important regulator of neuritogenesis activates MAPK and 
phosphoinositide-3 kinase (PI3K) cascades [118], known to be also regulated by estradiol. 
Moreover estradiol increases BDNF levels and the expression of TrkB (BDNF receptor), which 
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interacts with MAPK signalling cascade [119]. Therefore estradiol modulation of neuritogenis 
by stimulation of BDNF is proposed to be performed via MAPK signalling [103]. It has been also 
reported that notch signalling can be modulated by estradiol [120], promoting neuritogenesis 
by notch inhibition and consequently increasing the proneural gene, neurogenin 3 (Ngn3) 
[121].  
The estradiol influence on neuritogenesis have been attributed to the activation of c-
Src/Ras/ERK/CREB signalling and interaction with Notch signalling, IGF-I and BDNF.  Complex 
signalling cascades are involved adding to the interplay with external factors and expression, 
which depend on the brain region and neuron cell type. Therefore future studies are needed 
in order to clarify the molecular mechanisms that explain estradiol influence on 
neuritogenesis, namely in humans and under pathologic conditions.  
 
 
5.2. Endocannabinoids effect on neurite outgrowth 
 
The treatment with the endocannabinoid 2AG, agonist of the cannabinoid receptors CB1R, 
CB2R and GPR55 resulted in an alteration of the hiPSC derived glutamatergic cortical neurons 
morphology. The response at such an early stage of maturation provides evidence for the 
presence of cannabinoid receptors since embryonic stages till adulthood [3]. Despite the 
opposite behaviour of CB1 and CB2 receptors along neuronal differentiation, with an increase 
of CB1 levels and a decrease of CB2 concentration, at a neural progenitor stage the activation 
of both CB1 and CB2 receptors have been associated to influence cell fate, proliferation, 
differentiation and migration [122].  In adulthood the expression of the cannabinoid receptors 
is quite heterogeneous, CB1 receptors are mainly present at central and peripheral nervous 
system and CB2Rs are expressed in immune cells in and outside the nervous system [75] 
.Within the central nervous system the CB1 receptor is present at high concentrations in the 
basal ganglia, frontal cortex, hippocampus and cerebellum [2], being expressed namely at the 
GABAergic interneurons and glutamatergic neurons [123]. The differentiation of iPSC into 
glutamatergic cortical neurons and posterior alterations of the neuron structure that resulted 
from treatment with the endocannabinoid 2AG suggests the presence of the cannabinoid 
receptor CB1. However further studies would be necessary to confirm this observations.  
The stimulation of neurite outgrowth and neuronal differentiation has been associated to 
the nerve growth factor (NGF) receptor, TrkA and G-protein coupled receptors (GPCRs) [104]. 
GPCRs can be activated trough different mechanisms, as Drd2 dopamine D2 receptors in 
cortical neurons [124], serotonin 1-B receptors in thalamic neurons [125] as well as 
cannabinoid receptors. The stimulation of the cannabinoid receptors on Neuro2A cells by the 
endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2AG) have been implicated 
on neuron differentiation and neurite outgrowth [126]. The activation of these receptors, 
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coupled to GPCRs inhibits cAMP production by adenylyl cyclases and activates protein kinases 
as Src, MAPK 1/2 and Akt  [104], resulting in the stimulation of neurite outgrowth and 
modulation of neuronal differentiation. CBR1 has been associated to the activation of these 
kinases and activation of the transcriptional factors CREB and Stat3 [104], known to be 
involved in neuritogenesis [9]. Additionally, PI3K-PAX6 a signalling pathway that regulates 
neuronal differentiation, has been found to be activated in response to cannabinoid signalling 
[127] delineated from an in silico gene regulatory network approach. Therefore, my data 
shows that the introduction of the endocannabinoid during neurite elongation changed the 
regular path of neuritogenesis by an increase of neurite length and complexity, explained by 
the number of branches. This alteration in neurite outgrowth has been reported by previous 
studies on Neuro2A cells [126] and has also been assessed to have effect in axon growth, the 
following stage of neuritogenesis. Harkany and colleagues using a CB1R knockout pyramidal 
neuron-specific and GABA-ergic interneuron specific mouse along with endocannabinoid 
signalling, found that eCBs act as axon guidance cues that lead to proper patterning of this 
neurons during brain development [128, 129]. 
 The implications of the cannabinoid signalling in hiPSC derived neurons it‘s still in its 
preliminary steps and future experiments are needed to confirm the obtained results. 
Moreover it is mandatory to first standardize the protocol till further experiments are 
performed. However, despite the limitations engaged to the use of iPSC and the drawbacks 
found during the development of the project, under these conditions cells showed a positive 
response to endocannabinoid stimulation, which encourages further studies on this regards.  
 
5.3.  hiPSC differentiation : limitations  
 
The 24 hour treatment of the differentiated hiPSC cortical neurons resulted in divergent 
effects between experiments and cell lines, not only between clones from the same patient 
but also among clones of the same individual. Therefore several questions can be addressed, 
firstly in respect to the different results obtained for each cell line, between experiments; 
and secondly in regards to the different responses between the four cell lines. 
As referred before, the image analysis software MetaMorph (Neurite Outgrowth) requires 
a low density of differentiated cells, which was achieved at the end of the project, on the 
third experiment. As illustrated on figures 4.2 (―Cell density optimization‖) and 4.4 
(―Segmented images after process and analysis with NeuriteOutgrowth‖) the differences on 
cell density between experiments are visible in all four cell lines, decreasing from EXP M1 to 
EXP M3. For the parameters that are being analysed it is required a low density of cells. 
Cells plated at high cell density leads to the differentiation of cells tightly spaced that 
causes the overlap of neurites of distinct neurons, as observed on EXP M1 (figures 4.2 (A) and 
4.4 (EXP M1)). With the use of a lower number of viable cells, cells are sparser and can be 
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analysed individually. Branch junctions can be distinguished from cross points (overlap of 
different neurites of the same neuron or different neurons) by changes in direction of neurite 
skeleton segments. However a high cell density increases cell overlapping, which could 
possibly influence the acquisition of the number of branch junctions per cell. As it is 
represented on figure 4.4, neurite tracing was not affected by the high values of cell density, 
since neurons are segmented. However it is important to note that neurites localized on the 
images boundaries can elongate beyond its limits. Therefore the full length of these neurites 
is not being quantified.  Despite plating cells at a low cell density, achievable by cell counting 
before terminal plating, a possible solution and future approach to surpass this drawback and 
improve neurite outgrowth analysis is the use of a lower magnification, such as a 10x 
objective. This way neurons full length is detected and more accurate values are obtained for 
the total number of neurons figured in the image.  
The hiPSC technology has a number of limitations, from technical to reproducibility and 
time consuming issues.  
In order to obtain gene expression similar to the brain, hiPSC neural progenitors need 8-16 
weeks of cell culture [130]. Therefore having the purpose of studying a neurodevelopmental 
disorder hiPSCs were differentiated for 30 days into immature glutamatergic neurons 
characterized by a pyramidal shape and the presence of neurites, demonstrating how hiPSCs 
cell culture is a time consuming in vitro experiment. This limitation was surrounded to some 
extent with the cryopreservation of the cell lines and posterior addition of bFGF that allowed 
having stocks of cell lines at neural passage 3. 
Another important issue related to the use of hiPSCs is the variability between hiPSCs 
lines, among independent clones derived from a single patient and from hiPSC derived from 
different patients. Differences detected in different cell lines, phenotypic variations and even 
genetic mutations force the use of several cell lines in order to acquire consistent results. 
However a high cost of cell culture limits this solution that leads to the use of a low number 
of cell lines in most cases.  In the present study four cell lines derived from two different 
patients were used.  
Despite deriving from the same individual, inta-patient variability was verified. Different 
responses were observed from clones derived from the same individual. The cell lines 
CT.M2.42 and CT.M2.05 had a positive response to E2, PPT and 2AG, and WAY respectively, 
demonstrating how two cell lines from the same donor can exhibit different responses. 
Moreover the morphology of hiPSCs derived neurons from CT.M1.04 was affected after 
treatment with PPT and 2AG, whereas CT.M1.11 did not respond to any treatment. Genetic 
variability possibly derived from the reprogramming process is one of the cause that is 
normally given. Adding to this spontaneous mutations occur naturally being harder to avoid. 
Therefore high quality control protocols are needed such as morphological, gene expression 
and karyotype analyses, tests for contaminants, and with RNA and DNA methylation profiling. 
  
53 
Furthermore the use of neural progenitors at earlier passages will decrease the possibility of 
mutations to occur. 
Table 4.1 provides a summary of the responses of the different cell lines, showing both 
intra-patient variability but also inter-patient patient variability. Divergences between hiPSC 
cell lines derived from different patients were observed, despite the consistent response to 
PPT and 2AG between clones of different patients.  
Inter-patient variability has been commonly documented, such as changes on 
differentiation efficiencies and electrophysiological properties, which has been associated to 
the identity and sex of the donor [131, 132]. The creation of isogenic hiPSC cell lines has the 
ability to overtake this limitation, despite requiring genetic manipulation as has been 
proposed [96].   
The different responses observed between the four cell lines, leads to the question of 
reproducibility. In order to attest the reproducibility of the technique and protocol used, and 
to confirm the effects obtained by the acute steroid and endocannabinoid treatments at day 
29, it is needed to reproduce the experience and standardize the protocol.  
Over the time, with the advances of stem cell technology different solutions have been 
implemented in order to surpass these limitations and reproduce results. The use of standard 
protocols, cell culture media and differentiation kits have been increasing in the market [96], 
for instances, in order to minimize these limitations and obtain consistent neuronal cultures.   
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  Chapter 6.
 Conclusions 
Schizophrenia is a psychiatric disorder with unknown etiology and no treatment, being 
patients only medicated to attenuate the symptoms. Therefore investment has been made in 
demand of potential treatments not only of the positive and negative symptoms but also to 
take over the cognitive deficits. In order to achieve this goal the use of adequate model 
systems is necessary.  
Over the past few years iPSC technology has been evolving and demonstrating to be a 
proper system for the study of neurodevelopmental disorders as Schizophrenia. Therefore 
hiPSCs were used in order to study the effects of two potential therapeutics of this disorder. 
Neurosteroids, estrogens and testosterone (estrogen precursor), have been demonstrated to 
enhance acquisition and memory consolidation, on both males and females [109]; and also 
endocannabinoids, reported to express differently from early embryonic stages until 
adulthood, but to affect cognition [2], which is highlighted by the consumption of plant-
derived cannabis, an environmental risk factor to develop Schizophrenia [133]. 
Therefore the effect of neurosteroids and endocannabinoids was studied using hiPSCs 
derived cortical neurons, which was analysed using MetaMorph, an image analysis software. 
Despite the variability and reproducibility of the results between experiments and cell lines, 
intra- and inter- variability characteristic of iPSC use, the different treatments stimulated 
neuron elongation and ramification that mirrors an increase in neuron arborization.  
Glutamatergic cortical neurons differentiated for 30 days were responsive to 17β-estradiol 
and to the classical ERs, ERα and ERβ, by the activation of the correspondent receptors 
performed by PPT and WAY200070 agonists, which was observed by an increase in neurite 
length as well as in number of branches per cell. Treatment with the endocannabinoid, 2AG, 
also reflected an increase in neurite outgrowth providing evidence of its role in 
neuritogenesis.   
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Further studies are needed, firstly to standardize the protocol to then reproduce the 
experiments and verify the obtained results. Moreover as a future experiment, different 
concentrations of the drugs should be tested namely for G1 and testosterone, which did not 
change neuron structure. Western Blot tests and quantitative q-PCR, for instances, can be 
also used as a way to study the signalling network that triggers neurite outgrowth by the 
different treatments used.   
Despite the variability of iPSC and the drawbacks of this preliminary approach, the data 
presented here demonstrates the ability of hiPSCs to model Schizophrenia and to study 
possible treatments. The use of this model allowed the investigation of the different 
treatments in neuritogenesis revealing promising results, alluring for future research.   
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Annexes  
Section A - Neuralization protocol – reagents 
 
 
Table A.1 - Catalogue number of the reagents used in cell culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagent Company : Catalogue Number 
Geltrex Life Technologies : A1413302 
HBSS Invitrogen : 14170146 
Versene Lonza : BE17-711E 
E8 Medium Life Technologies : A1517001 
ROCKi Sigma : Y0503 
Accutase Invitrogen :  a1110501 
N2 Supplement Life Technologies : 17502-048 
DMEM/F12 Sigma : D6421 
B27 Supplement Life Technologies : 17504-044 
Neurobasal Medium Life Technologies : 21103-049 
L- Glutamax Life Technologies : 35050-038 
SB431542 Cambridge Bioscience : ZRD-SB-50 
Dorsomorphin Sigma : P5499 
AA2P Sigma : A4403 
bFGF Life Technologies : 13256-029 
Β-mercaptoethanol Life technologies : 31350010  
Insulin, Human recombinant (10mg/mL) Sigma : I9278-5Ml 
NEAA Life technologies :  11140-050 
DAPT Sigma :  D5942  
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Table A. 2 - Preparation of N2 and B27 medium for a total volume of 50mL. 
N2 medium (50 mL) 
DMEM/F12 48,5 mL 
N2 serum 500µL 
L-glutamax 500µL 
NEAA 500µL 
Β-mercaptoethanol 350µL 
Insulin 25µL 
 
 
Table A.3 - Neuralization medium used during neuronal differentiation. 
Concentration of the reagents. 
Days Neuralization medium (reagent) 
Day 1  -  Day 8 
 
N2 medium (table 9.2 (a)) (50%) 
B27 medium (table 9.2 (b)) (50%) 
SMADi (1µM dorsomorphin + 10µM SB431542) 
Day 8  -  Day 12 N2:B27 
Day 13  -  Day 17 N2:B27 + AA2P (200µM)  
Day 17  -  Day 20 N2:B27 + AA2P + BFGF (10ng/mL)) 
Day 21 – Day 27 B27 + AA2P + DAPT (10µM)  
Day 28 – Day 30 B27 + AA2P  
 
Section B - Immunocytochemistry (ICC) – further information 
 
DABCO Antifade recipe 
 
Table B.14 - Reagents included in DABCO (SIGMA : D2522) recipe. 
 
 
 
 
B27 medium (50 mL) 
Neurobasal medium 48,5 mL 
  
B27 serum 1,0mL 
  
L-glutamax 500µL 
  
Reagentes Volume 
DABCO 0.233g 
TRIS-HCl 1M (ph 8.0) 200µl 
Sterile H2O 800µL 
86% Glycerol 9mL 
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